Rafael (RFL) 10-K 30 Oct 23 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Jul. 31, 2023	Oct. 27, 2023	Jan. 31, 2023
Document Information Line Items
Entity Registrant Name	RAFAEL HOLDINGS, INC.
Trading Symbol	RFL
Document Type	10-K
Current Fiscal Year End Date	--07-31
Entity Public Float			$ 70.2
Amendment Flag	false
Entity Central Index Key	0001713863
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jul. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-55863
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2296593
Entity Address, Address Line One	520 Broad Street
Entity Address, City or Town	Newark
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07102
City Area Code	(212)
Local Phone Number	658-1450
Title of 12(b) Security	Class B common stock, par value $0.01 per share
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	596
Auditor Name	CohnReznick LLP
Auditor Location	New York, New York
Class A Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		787,163
Class B Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		23,719,472

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 21,498	$ 26,537
Available-for-sale securities	57,714	36,698
Interest receivable	387	140
Convertible note receivable, related party	1,921
Accounts receivable, net of allowance for doubtful accounts of $245 and $197 at July 31, 2023 and July 31, 2022, respectively	213	157
Prepaid expenses and other current assets	914	4,621
Assets held-for-sale		40,194
Investment in equity securities	294
Total current assets	82,941	108,347
Property and equipment, net	1,695	1,770
In-process research and development and patents	1,575	1,575
Other assets	9	1,387
TOTAL ASSETS	98,829	118,320
CURRENT LIABILITIES
Accounts payable	333	564
Accrued expenses	763	1,875
Other current liabilities	1,023	3,518
Note payable, net of debt issuance costs, held-for-sale		15,000
Total current liabilities	2,145	21,026
Other liabilities	55	88
TOTAL LIABILITIES	2,200	21,114
COMMITMENTS AND CONTINGENCIES
EQUITY
Additional paid-in capital	264,010	262,023
Accumulated deficit	(167,333)	(165,457)
Accumulated other comprehensive loss related to unrealized loss on available-for-sale securities	(353)	(63)
Accumulated other comprehensive income related to foreign currency translation adjustment	3,725	3,767
Total equity attributable to Rafael Holdings, Inc.	100,293	100,515
Noncontrolling interests	(3,664)	(3,309)
TOTAL EQUITY	96,629	97,206
TOTAL LIABILITIES AND EQUITY	98,829	118,320
Class A Common Stock
EQUITY
Common stock value	8	8
Class B Common Stock
EQUITY
Common stock value	236	237
Other Pharmaceuticals
CURRENT ASSETS
Investments	65	477
Hedge Funds
CURRENT ASSETS
Investments	4,984	4,764
Day Three Labs Inc
CURRENT ASSETS
Investments	2,797
Cyclo Therapeutics Inc
CURRENT ASSETS
Investments	4,763
Related Party
CURRENT LIABILITIES
Other current liabilities	$ 26	$ 69

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Allowance for doubtful accounts (in Dollars)	$ 245	$ 197
Class A Common Stock
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares issued	787,163	787,163
Common stock, shares outstanding	787,163	787,163
Class B Common Stock
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	23,635,709	23,712,449
Common stock, shares outstanding	23,490,527	23,687,964

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
REVENUE
Total revenue	$ 279	$ 410
COSTS AND EXPENSES
General and administrative	8,932	16,978
Research and development	6,312	8,742
Depreciation and amortization	78	72
Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit		25,000
Provision for losses on related party receivables		10,095
Loss from operations	(15,043)	(60,477)
Interest expense		(6)
Interest income	3,253	201
Impairment of investments - Other Pharmaceuticals	(334)
Impairment of cost method investment - Cornerstone Pharmaceuticals		(79,141)
Realized gain (loss) on available-for-sale securities	154	(45)
Realized gain on investment in equity securities	309
Unrealized gain on investment in equity securities	33
Unrealized gain (loss) on investments	33
Loss from continuing operations before income taxes	(8,745)	(139,972)
Benefit from income taxes	255
Consolidated net loss from continuing operations	(8,693)	(140,547)
Discontinued Operations (Note 3)
Loss from discontinued operations related to 520 Property	(306)	(1,830)
Gain on disposal of 520 Property	6,784
Income (loss) from discontinued operations	6,478	(1,830)
Consolidated net loss	(2,215)	(142,377)
Net loss attributable to noncontrolling interests	(339)	(17,719)
Net loss attributable to Rafael Holdings, Inc.	(1,876)	(124,658)
OTHER COMPREHENSIVE LOSS
Consolidated net loss	(2,215)	(142,377)
Unrealized loss on available-for-sale securities	(290)	(63)
Foreign currency translation adjustment	(42)	(5)
Total comprehensive loss	(2,547)	(142,445)
Comprehensive loss attributable to noncontrolling interests	(336)	(17,746)
Total comprehensive loss attributable to Rafael Holdings, Inc.	$ (2,211)	$ (124,699)
Basic and diluted:
Continuing operations (in Dollars per share)	$ (0.36)	$ (6.22)
Discontinued operations (in Dollars per share)	0.28	(0.09)
Total basic and diluted loss per share (in Dollars per share)	$ (0.08)	$ (6.31)
Weighted average number of shares used in calculation of loss per share
Basic and diluted (in Shares)	23,263,211	19,767,342
Rental – Third Party
REVENUE
Total revenue	$ 171	$ 179
Rental – Related Party
REVENUE
Total revenue	108	111
Other – Related Party
REVENUE
Total revenue		120
Cyclo Therapeutics Inc
COSTS AND EXPENSES
Unrealized gain (loss) on investments	2,663
Hedge Funds
COSTS AND EXPENSES
Unrealized gain (loss) on investments	220	(504)
Day Three Labs Inc
COSTS AND EXPENSES
Equity in loss	(203)
RP Finance
COSTS AND EXPENSES
Equity in loss		$ (575)

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Income Statement [Abstract]
Continuing operations - basic and diluted (in Dollars per share)	$ (0.36)	$ (6.22)
Loss per common share - basic and diluted (in Dollars per share)	0.28	(0.09)
Total diluted loss per share (in Dollars per share)	$ (0.08)	$ (6.31)
Basic and diluted (in Shares) (in Shares)	23,263,211	19,767,342

Consolidated Statements of Shar

Consolidated Statements of Shareholders Equity (Deficit) - USD ($) $ in Thousands	Series A Common Stock	Series A	Series B Common Stock	Series B	Additional Paid-in Capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests	Total
Balance at Jul. 31, 2021	$ 8		$ 169		$ 159,136	$ (40,799)	$ 3,772	$ 14,418	$ 136,704
Balance (in Shares) at Jul. 31, 2021	787,163		16,936,864
Net loss						(124,658)		(17,719)	(142,377)
Stock-based compensation			$ 16		18,045				18,061
Stock-based compensation (in Shares)			1,533,311
Forfeiture of restricted stock			$ (9)		(18,969)				(18,978)
Forfeiture of restricted stock (in Shares)			(943,305)
Common stock sold to investors			$ 28		99,142				99,170
Common stock sold to investors (in Shares)			2,833,425
Transaction costs incurred in connection with sale of common stock					(6,228)				(6,228)
Common stock sold to related party			$ 33		10,964				10,997
Common stock sold to related party (in Shares)			3,338,307
Shares withheld for payroll taxes					(75)				(75)
Shares withheld for payroll taxes (in Shares)			(10,638)
Unrealized loss on available-for-sale securities							(63)		(63)
Acquisition of additional ownership interest in LipoMedix					8			(8)
Foreign currency translation adjustment							(5)		(5)
Balance at Jul. 31, 2022	$ 8		$ 237		262,023	(165,457)	3,704	(3,309)	97,206
Balance (in Shares) at Jul. 31, 2022	787,163	787,163	23,687,964	23,687,964
Net loss						(1,876)		(339)	(2,215)
Stock-based compensation			$ 2		3,089				3,091
Stock-based compensation (in Shares)			220,019
Forfeiture of restricted stock			$ (2)		(901)				(903)
Forfeiture of restricted stock (in Shares)			(296,759)
Shares withheld for payroll taxes			$ (1)		(217)				(218)
Shares withheld for payroll taxes (in Shares)			(120,697)
Unrealized loss on available-for-sale securities							(290)		(290)
Acquisition of additional ownership interest in LipoMedix					16			(16)
Foreign currency translation adjustment							(42)		(42)
Balance at Jul. 31, 2023	$ 8		$ 236		$ 264,010	$ (167,333)	$ 3,372	$ (3,664)	$ 96,629
Balance (in Shares) at Jul. 31, 2023	787,163	787,163	23,490,527	23,490,527

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Operating activities
Consolidated net loss	$ (2,215)	$ (142,377)
Less: Income (loss) from discontinued operations	6,478	(1,830)
Loss from continuing operations	(8,693)	(140,547)
Adjustments to reconcile consolidated net loss to net cash used in operating activities
Depreciation and amortization	78	72
Net unrealized (gain) loss on investments - Hedge Funds	(220)	504
Unrealized gain on equity securities	(33)
Unrealized gain in equity investments - Cyclo Therapeutics Inc.	(2,663)
Realized (gain) loss on available-for-sale securities	(154)	45
Amortization of discount on available-for-sale securities	(1,195)
Impairment of investments - Other Pharmaceuticals	334
Impairment of cost method investment - Cornerstone Pharmaceuticals		79,141
Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit		25,000
Equity in loss of RP Finance		575
Equity in loss of Day Three Labs Inc.	203
Provision for losses on related party receivables		10,095
Provision for doubtful accounts		4
Stock-based compensation, net	2,188	(917)
Change in assets and liabilities, net of effects from discontinued operations:
Trade accounts receivable	(117)	74
Interest receivable	(247)	(140)
Prepaid expenses and other current assets	373	(3,545)
Other assets	(27)	130
Accounts payable and accrued expenses	(827)	52
Other current liabilities	781	3,566
Due to related parties	(43)	(67)
Due from Cornerstone Pharmaceuticals		(120)
Other liabilities	15	40
Net cash used in continuing operations	(10,247)	(26,038)
Net cash used in discontinued operations	(639)	(41)
Net cash used in operating activities	(10,886)	(26,079)
Investing activities
Payment to Cornerstone Pharmaceuticals pursuant to Line of Credit		(25,000)
Purchases of property and equipment		(2)
Payment to fund RP Finance Line of Credit		(1,875)
Purchases of available-for-sale securities	(204,798)	(65,306)
Proceeds from the sale and maturities of available-for-sale securities	185,121	28,500
Issuance of convertible note receivable, related party	(2,000)
Proceeds from investments - Other Pharmaceuticals	78
Purchases of equity securities	(1,586)
Proceeds from sales of equity securities	1,325
Purchase of Investment in Day Three Labs Inc.	(3,000)
Purchase of Investment in Cyclo Therapeutics Inc.	(2,100)
Net cash used in investing activities of continuing operations	(26,960)	(63,683)
Net cash provided by (used in) investing activities of discontinued operations	48,171	(113)
Net cash provided by (used in) investing activities	21,211	(63,796)
Financing activities
Proceeds from issuance of common stock		99,170
Proceeds from issuance of common stock from related party		10,997
Payment of transaction costs incurred in connection with sale of common stock		(6,228)
Payments for taxes related to shares withheld for employee taxes	(218)	(75)
Net cash (used in) provided by continuing operations	(218)	103,864
Net cash used in financing activities of discontinued operations	(15,000)
Net cash (used in) provided by financing activities	(15,218)	103,864
Effect of exchange rate changes on cash and cash equivalents	(146)	(306)
Net (decrease) increase in cash and cash equivalents	(5,039)	13,683
Cash and cash equivalents, beginning of year	26,537	12,854
Cash and cash equivalents, end of year	21,498	26,537
Non-cash supplemental disclosure
Acquisition of additional ownership interest in LipoMedix	$ 16	$ 8

Description of Business

Description of Business	12 Months Ended
	Jul. 31, 2023
Description of Business [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 – DESCRIPTION OF BUSINESS Description of Business Rafael Holdings, Inc. (NYSE:RFL), (“Rafael Holdings”, “we” or the “Company”), a Delaware corporation, is a holding company with interests in clinical and early-stage pharmaceutical companies (the “Pharmaceutical Companies”), including an investment in Cornerstone Pharmaceuticals, Inc. (“Cornerstone”), formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, a majority equity interest in LipoMedix Pharmaceuticals Ltd. (“LipoMedix”), a clinical stage pharmaceutical company, the Barer Institute Inc. (“Barer”), a wholly-owned preclinical cancer metabolism research operation, an investment in Cyclo Therapeutics Inc. (Nasdaq: CYTH), (“Cyclo Therapeutics” or “Cyclo”), a clinical-stage biotechnology company dedicated to developing life-changing medicines for patients and families living with challenging diseases through its lead therapeutic asset, Trappsol ® . , (“Rafael Medical Devices” and Day Three Labs together with the Pharmaceutical Companies, represent our “Investment Companies”). Historically, the Company owned multiple real estate assets. In 2020, the Company sold an office building located in Piscataway, New Jersey and, on August 22, 2022, the Company sold the building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and several tenants and an associated public garage (the “520 Property”). See Note 3 for further details on the sale transaction. Currently, the Company holds a portion of a commercial building in Jerusalem, Israel as its remaining real estate asset. The Company holds debt and equity investments in Cornerstone Pharmaceuticals that includes preferred and common equity interests and a warrant to purchase additional equity. On June 17, 2021, the Company entered into a merger agreement to acquire full ownership of Cornerstone Pharmaceuticals in exchange for issuing Company Class B common stock to the other stockholders of Cornerstone Pharmaceuticals (“Merger Agreement” or “Merger”). On October 28, 2021, the Company announced that the AVENGER 500 Phase 3 clinical trial for CPI-613 ® Cornerstone is in the process of a comprehensive restructuring transaction including, the conversion of the debt under the Line of Credit Agreement and the Promissory Note held by the Company, the conversion and modification of other Cornerstone debt obligations, the extension of the Cornerstone debt held by RP Finance, a reverse stock split, the conversion of all outstanding preferred stock of Cornerstone into common stock and the adoption of certain governance measures. This transaction is subject to a number of conditions which are beyond the Company’s control. In May 2023, the Company invested in Cyclo Therapeutics. Cyclo is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Cyclo’s lead drug candidate is Trappsol ® ® ® ® In 2019, the Company established Barer, a preclinical cancer metabolism research operation, to focus on developing a pipeline of novel therapeutic compounds, including compounds to regulate cancer metabolism with potentially broader application in other indications beyond cancer. Barer has been comprised of scientists and academic advisors that are experts in cancer metabolism, chemistry, and drug development. In addition to its own internal discovery efforts, Barer pursued collaborative research agreements and in-licensing opportunities with leading scientists from top academic institutions. Barer’s subsidiary, Farber Partners, LLC (“Farber”), was formed around one such agreement with Princeton University’s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program. In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute. In 2016, the Company first invested in LipoMedix, a clinical stage pharmaceutical company and holds a majority of the common stock. In April 2023, the Company invested in Day Three Labs, the majority-owner of Day three Labs Manufacturing, a company which reimagines existing cannabis offerings with pharmaceutical-grade technology and innovation like Unlokt™ to bring to market better, cleaner, more precise and predictable products in the cannabis industry. In May 2021, the Company formed Rafael Medical Devices, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. In August 2023, the Company raised $925,000 from third parties in exchange for 31.62% ownership of Rafael Medical Devices. The Company also holds a 95% investment in LipoMedix, a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. The “Company” in these consolidated financial statements refers to Rafael Holdings and its subsidiaries on a consolidated basis. All majority-owned subsidiaries are consolidated with all intercompany transactions and balances eliminated in consolidation. In addition to Rafael Holdings, Inc., the subsidiaries included in these consolidated financial statements are as follows: Company Country of Incorporation Percentage Owned Broad Atlantic Associates, LLC United States – Delaware 100 % IDT R.E. Holdings Ltd. Israel 100 % Rafael Holdings Realty, Inc. United States – Delaware 100 % Barer Institute, Inc. United States – Delaware 100 %* The Barer Institute, LLC United States – Delaware 100 %* Hillview Avenue Realty, JV United States – Delaware 100 % Hillview Avenue Realty, LLC United States – Delaware 100 % Rafael Medical Devices, Inc. United States – Delaware 100 % Levco Pharmaceuticals Ltd. Israel 95 %*** Farber Partners, LLC United States – Delaware 93 % Pharma Holdings, LLC United States – Delaware 90 % LipoMedix Pharmaceuticals Ltd. Israel 95 %**** Altira Capital & Consulting, LLC United States – Delaware 67 % CS Pharma Holdings, LLC United States – Delaware 45 %** * In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities. ** 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma and Pharma Holdings, collectively own securities representing 51% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). Refer to Note 4 for further details. *** During Fiscal 2022, the Company discontinued further material investment in Levco. **** On February 9, 2023, the Company increased its ownership interest in LipoMedix Pharmaceuticals Ltd. an additional 11% from 84% to 95%. On March 15, 2022, the Company dissolved IDT 225 Old NB Road, LLC.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal year 2023 refers to the fiscal year ended July 31, 2023). The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. GAAP. The accompanying consolidated financial statements reflect the activity related to the 520 Property as discontinued operations. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. Liquidity As of July 31, 2023, the Company had cash and cash equivalents of approximately $21.5 million, and available-for-sale securities valued at approximately $57.7 million. On August 22, 2022, the Company received net proceeds of approximately $33 million in connection with the sale of the 520 Property (see Note 3 for further details). The Company expects the balance of cash and cash equivalents, and available-for-sale securities to be sufficient to meet its obligations for at least the next 12 months from the issuance of these consolidated financial statements. Concentration of Credit Risk and Significant Customers The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For the year ended July 31, 2023, including revenue from discontinued operations, related parties represented 42% of the Company’s revenue. As of July 31, 2023, there were two customers which represented 27% and 47% of the Company’s accounts receivable balance. For the year ended July 31, 2022, including revenue from discontinued operations, related parties represented 58% of the Company’s revenue, and as of July 31, 2022, two customers, one of which is a related party, represented 24% and 47% of the Company’s accounts receivable balance, respectively. Cash and Cash Equivalents The Company considers all liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Reserve for Receivables The Company evaluates accounts receivable, loans, interest and fees receivable for impairment under Accounting Standards Codification (“ASC”) 310, Receivables The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The allowance is determined based on known troubled accounts, historical experience and other currently available evidence. Doubtful accounts are written off upon final determination that the trade accounts will not be collected. The computation of this allowance is based on the tenants’ or parking customers’ payment histories, as well as certain industry or geographic specific credit considerations. If the Company’s estimates of collectability differ from the cash received, then the timing and amount of the Company’s reported revenue could be impacted. The credit risk is mitigated by the high quality of the Company’s existing tenant base, inclusive of related parties, which represented 42% and 58% of the Company’s total revenue for the years ended July 31, 2023 and 2022, respectively. The Company recorded bad debt expense of approximately $110 thousand and $4 thousand for the years ended July 31, 2023 and 2022, respectively. Convertible Note Receivable, Related Party The Convertible Note Receivable is classified as available-for-sale as defined under ASC 320, Investments - Debt and Equity Securities The fair value of the Convertible Note Receivable is estimated using a scenario-based analysis based on the probability-weighted present value of future investment returns, considering each of the possible outcomes available to the Company, including cash repayment, equity conversion, and collateral transfer scenarios. Estimating the fair value of the convertible note requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Variable Interest Entities In accordance with ASC 810, Consolidation If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Investments The method of accounting applied to long-term investments in equity securities involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also include the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated. Investments in equity securities may be accounted for using (i) the fair value option if elected, (ii) fair value through earnings if fair value is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. The Company has elected the fair value option to account for its investment in Cyclo Therapeutics Inc. over which the Company has significant influence. The fair value option is irrevocable once elected. The Company measured its initial investment in Cyclo at fair value and shall record all subsequent changes in fair value in earnings in the consolidated statement of operations. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 9, “Investments.” Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for in accordance with ASC 321, Investments - Equity Securities Investments - Hedge Funds The Company accounts for its investments in hedge funds in accordance with ASC 321, Investments – Equity Securities Corporate Bonds and US Treasury Bills The Company’s marketable securities are considered to be available-for-sale as defined under ASC 320, Investments - Debt and Equity Securities Cost Method Investment The Company has determined that Cornerstone Pharmaceuticals (see Note 4) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Cornerstone Pharmaceuticals that most significantly impact Cornerstone Pharmaceuticals’ economic performance. Equity Method Investments The Company has determined that each of RP Finance, LLC (“RP Finance”) and Day Three Labs, Inc. (“Day Three”, RP Finance and Day Three, collectively, the “Equity Method Investees” and the Company’s investments in RP Finance and Day Three, collectively, the “Equity Method Investments”), (see Note 6 and Note 8), are each a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of the Equity Method Investees that most significantly impact the Equity Method Investees’ economic performance and, therefore, is not required to consolidate the Equity Method Investees. The Company accounts for the Equity Method Investments using the equity method of accounting. Long-Lived Assets Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, which range as follows: Classification Years Building and improvements 40 Tenant improvements 7-15 Other (primarily equipment and furniture and fixtures) 5 Properties On August 22, 2022, Broad Atlantic Associates LLC, a wholly-owned subsidiary of the Company (“Broad Atlantic”), completed the sale of the 520 Property for a purchase price of $49.4 million. The 520 Property served as the Company’s headquarters and had several other tenants, and a related 800-car public parking garage. The Company determined that the 520 Property met the held-for-sale and discontinued operations criteria as of July 1, 2022. The 520 Property was disposed of on August 22, 2022. The Company owns a portion of the 6th floor of a building located at 5 Shlomo Halevi Street, in Jerusalem, Israel. Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, which include property and equipment and in-process research and development and patents whenever significant events or changes in circumstances indicate that its carrying amount may not be recoverable. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a change to operating results. For the years ended July 31, 2023 and 2022, the Company determined that there was no impairment of its long-lived assets. Assets Held-for-Sale and Discontinued Operations The Company classifies assets as held-for-sale if all held-for-sale criteria are met pursuant to ASC 360-10, Property, Plant and Equipment Strategic changes in the Company’s operations can be considered a discontinued operation if both the operations and cash flows of the discontinued component have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued component after the disposal transaction. The results of the discontinued operations shall be reflected as a discontinued operation on the consolidated statements of operations and comprehensive loss and prior periods shall be recast to reflect the earnings from discontinued operations. As a result of the agreement to sell the 520 Property, the accompanying consolidated financial statements reflect the activity related to the sale of the 520 Property as discontinued operations. The Company determined that the 520 Property met the held-for-sale and discontinued operations criteria as of July 1, 2022. The 520 Property was disposed of on August 22, 2022. See Note 3 for additional information regarding the results, major classes of assets and liabilities, significant non-cash operating items, and capital expenditures of discontinued operations. Debt Issuance Costs Debt issuance costs are recorded net against the related debt and amortized to interest expense over the life of the related debt. During the years ended July 31, 2023 and 2022, amortized debt issuance costs of $0 and $472 thousand, respectively, were recorded as a component of interest expense which is included in Discontinued Operations. Revenue Recognition The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases The revenue derived from the 520 Property, which included leasing office and parking space to the tenants, is presented within discontinued operations in the consolidated statements of operations and comprehensive loss. Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earned revenue from parking which was derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and was accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due. Research and Development Costs Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property. Repairs and Maintenance The Company charges the cost of repairs and maintenance, including the cost of replacing minor items not constituting substantial betterment, to selling, general and administrative expenses as these costs are incurred. Stock-Based Compensation The Company accounts for stock-based compensation using the provisions of ASC 718, Stock-Based Compensation Income Taxes The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of such change. The Company uses a two-step approach for recognizing and measuring tax benefits taken or expected to be taken in a tax return. The Company determines whether it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, the Company presumes that the position will be examined by the appropriate taxing authority that has full knowledge of all relevant information. Tax positions that meet the more-likely-than-not recognition threshold are measured to determine the amount of tax benefit to recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Differences between tax positions taken in a tax return and amounts recognized in the financial statements will generally result in one or more of the following: an increase in a liability for income taxes payable, a reduction of an income tax refund receivable, a reduction in a deferred tax asset, or an increase in a deferred tax liability. The Company classifies interest and penalties on income taxes as a component of income tax expense, if any. Contingencies The Company accrues for loss contingencies when both (a) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements and (b) the amount of loss can reasonably be estimated. When the Company accrues for loss contingencies and the reasonable estimate of the loss is within a range, the Company records its best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company discloses an estimated possible loss or a range of loss when it is at least reasonably possible that a loss may have been incurred. Leases The Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments. As of July 31, 2023 and 2022, the Company was not a lessee under any leasing arrangements. Fair Value Measurements Fair value of financial and non-financial assets and liabilities is defined as an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three-tier hierarchy for inputs used to measure fair value, which prioritizes the inputs to valuation techniques used to measure fair value, is as follows: ● Level 1 - quoted prices in active markets for identical assets or liabilities; ● Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or ● Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy. Functional Currency The U.S. Dollar is the functional currency of our entities operating in the United States. The functional currency for our subsidiaries operating outside of the United States is the New Israeli Shekel, the currency of the primary economic environment in which such subsidiaries primarily expend cash. The Company translates those subsidiaries’ financial statements into U.S. Dollars. The Company translates assets and liabilities at the exchange rate in effect as of the consolidated financial statement date, and translates accounts from the consolidated statements of operations and comprehensive loss using the weighted average exchange rate for the period. The Company reports gains and losses from currency exchange rate changes related to intercompany receivables and payables, currently in non-operating expenses. Loss Per Share Basic loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per share is determined in the same manner as basic loss per share, except that the number of shares is increased to include restricted stock still subject to risk of forfeiture and to assume exercise of potentially dilutive stock options using the treasury stock method, unless the effect of such increase would be anti-dilutive. The Company uses income from continuing operations as the “control number” or benchmark to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting earnings (loss) per share for discontinued operations. Recently Issued Accounting Standards Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

Discontinued Operations

Discontinued Operations	12 Months Ended
	Jul. 31, 2023
Discontinued Operations [Abstract]
DISCONTINUED OPERATIONS	NOTE 3 – DISCONTINUED OPERATIONS On July 1, 2022, the Company determined that the 520 Property met the held-for-sale criteria and the Company therefore classified the 520 Property as held-for-sale in the consolidated balance sheets at July 31, 2022. The sale of the 520 Property also represented a significant strategic shift that will have a major effect on the Company’s operations and financial results. Therefore, the Company has classified the results of operations related to the 520 Property as discontinued operations in the consolidated statements of operations and comprehensive loss. Depreciation on the 520 Property ceased on July 1, 2022, as a result of the 520 Property being classified as held-for-sale. On August 22, 2022, Broad Atlantic completed the sale of the 520 Property for an aggregate gross purchase price of $49.4 million. The 520 Property was encumbered by a mortgage securing a $15 million note payable which was paid off in this transaction. Refer to Note 15 for further information on the note payable. After repaying the note payable, commissions, taxes, and other related costs, the Company received a net cash amount of approximately $33 million at closing. The carrying value of major classes of assets and liabilities related to discontinued operations at July 31, 2022 was as follows: As of (in thousands) Current assets held-for-sale Building and Improvements $ 45,437 Land 10,412 Furniture and Fixtures 1,145 Other 205 Property and equipment 57,199 Less Accumulated Depreciation (17,005 ) Property and equipment, net 40,194 Total current assets held-for-sale 40,194 Total assets held-for-sale $ 40,194 Current liabilities held-for-sale Total current liabilities $ 15,000 The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was $0 and approximately $150 thousand as of July 31, 2023 and 2022, respectively. The noncurrent portion of deferred rental income included in Other Assets was $0 Discontinued operations include (i) rental and parking revenues, (ii) payroll, benefits, facility costs, real estate taxes, consulting and professional fees dedicated to the 520 Property, (iii) depreciation and amortization expenses and (iv) interest (including amortization of debt issuance costs) on the note payable on the 520 Property. The operating results of these items are presented in our consolidated statements of operations and comprehensive loss as discontinued operations for all periods presented. The following table details the components comprising net loss from our discontinued operations: Year Ended July 31, 2023 2022 (in thousands) Revenue from discontinued operations: Rental – Third Party $ 68 $ 644 Rental – Related Party 115 2,161 Parking 66 694 Total revenue from discontinued operations 249 3,499 Costs and expenses from discontinued operations: General and administrative 468 2,683 Depreciation and amortization — 1,317 Loss from discontinued operations (219 ) (501 ) Other income — 157 Interest expense (87 ) (1,486 ) Loss from discontinued operations (306 ) (1,830 ) Gain on disposal of discontinued operations 6,784 — Gain (loss) from discontinued operations $ 6,478 $ (1,830 ) The gain on disposal of discontinued operations of approximately $6.8 million was derived from the gross proceeds of approximately $49.4 million from the sale of the 520 Property, less the carrying value of the 520 Property of approximately $40.2 million, net of approximately $1.2 million in transaction costs and the write off of approximately $1.2 million of deferred rental income.

Investment in Cornerstone Pharm

Investment in Cornerstone Pharmaceuticals	12 Months Ended
	Jul. 31, 2023
Investment in Cornerstone Pharmaceuticals [Abstract]
INVESTMENT IN CORNERSTONE PHARMACEUTICALS	NOTE 4 – INVESTMENT IN CORNERSTONE PHARMACEUTICALS Equity Investment in Cornerstone Pharmaceuticals and Impairment of Cost Method Investment Cornerstone Pharmaceuticals is a clinical stage, cancer metabolism-based therapeutics company focused on the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The Company owns debt and equity interests and rights in Cornerstone Pharmaceuticals through a 90%-owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings. Pharma Holdings owns 50% of CS Pharma Holdings, LLC, or CS Pharma, a non-operating entity that owns equity interests in Cornerstone Pharmaceuticals. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma. A trust for the benefit of the children of Howard Jonas (Chairman of the Board and Executive Chairman and former Chief Executive Officer of the Company and Member of the Board of Cornerstone Pharmaceuticals) holds a financial instrument (the “Instrument”) that owns 10% of Pharma Holdings. Pharma Holdings holds 44.0 million shares of Cornerstone Pharmaceuticals’ Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Cornerstone Pharmaceuticals (the “Warrant”). The exercise price of the Warrant is the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments. On March 25, 2020, the Board of Directors of Cornerstone Pharmaceuticals extended the expiration date of the Warrant held by Pharma Holdings to purchase shares of the Warrant from December 31, 2020 to June 30, 2021, and on August 31, 2020 the Board of Directors of Cornerstone Pharmaceuticals further extended the expiration date of the Warrant held by Pharma Holdings, LLC to purchase shares of the Warrant to August 15, 2021. In connection with the Merger Agreement, the Warrant expiration was extended to April 1, 2022. The Company has asserted that it may be entitled to a further extension of the Warrant. At this time, the Company does not intend to exercise the Warrant. Pharma Holdings also holds certain governance rights in Cornerstone Pharmaceuticals including appointment of directors. Pharma Holdings is not the primary beneficiary of Cornerstone Pharmaceuticals as it does not control or direct the activities of Cornerstone Pharmaceuticals that most significantly impact Cornerstone Pharmaceuticals’ economic performance. CS Pharma holds 16.7 million shares of Cornerstone Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a $10 million Series D Convertible Note, with 3.5% interest, in Cornerstone Pharmaceuticals which was converted to shares of Series D Preferred Stock in January 2019. The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the Board of Cornerstone Pharmaceuticals, prior to any dividends to any other class of capital stock of Cornerstone Pharmaceuticals. In the event of any liquidation, dissolution or winding up of Cornerstone Pharmaceuticals, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class. The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Cornerstone Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle Pharma Holdings to 50% (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions. The Company evaluated its investments in Cornerstone Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures, The Company has determined that Cornerstone Pharmaceuticals is a VIE; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Cornerstone Pharmaceuticals that most significantly impact Cornerstone Pharmaceuticals’ economic performance. In addition, the interests held in Cornerstone Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in-substance common stock. The Instrument holds a contractual right to receive additional shares of Cornerstone Pharmaceuticals capital stock equal to 10% of the fully diluted capital stock of Cornerstone Pharmaceuticals (the “Bonus Shares”) upon the achievement of certain milestones. The additional 10% is based on the fully diluted capital stock of Cornerstone Pharmaceuticals, excluding the remainder for the Warrant, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Pharma Holdings holds the Warrant as well as other equity and governance rights in Cornerstone Pharmaceuticals. The Company currently owns 51% of the issued and outstanding equity in Cornerstone Pharmaceuticals. Approximately 8% of the issued and outstanding equity is owned by the Company’s subsidiary CS Pharma and 43% is held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds the Warrant. The Instrument holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any portion of the Warrant. Following any exercise, a portion of the Company’s interest in Cornerstone Pharmaceuticals would continue to be held for the benefit of the other equity holders in Pharma Holdings and CS Pharma. Cornerstone Pharmaceuticals may also issue additional equity interests, such as employee stock options, which will require the Company to pay additional cash to maintain the Company’s ownership percentage or exercise the Warrant in full. The terms of the Warrant provide that it expired on April 1, 2022; however, the Company has asserted that it may be entitled to a further extension of the Warrant. At this time, the Company does not intend to exercise the Warrant. Due to the Data Events, on October 28, 2021, the Company recorded an impairment charge of approximately $79.1 million related to the cost method investment in Cornerstone Pharmaceuticals representing the total amount of the Company’s cost method investment. The impairment loss was included in “Impairment of cost method investment – Cornerstone Pharmaceuticals” in the consolidated statements of operations and comprehensive loss for the year ended July 31, 2022. Approximately $17.3 million of the total impairment loss of $79.1 million was applicable to noncontrolling interests in certain of the Company’s subsidiaries and was allocated to the holders of interests in CS Pharma and Pharma Holdings in the approximate amounts of $10.4 million and $6.9 million, respectively. Line of Credit to Cornerstone Pharmaceuticals and Impairment of Related Receivable On September 24, 2021, the Company entered into a Line of Credit Loan Agreement (the “Line of Credit Agreement”) with Cornerstone Pharmaceuticals under which Cornerstone Pharmaceuticals borrowed $25 million from the Company. The first advance was in the amount of $1.9 million on September 24, 2021. On October 1, 2021, a second advance was made in the amount of $23.1 million. The Line of Credit Agreement accrues interest at 9% per annum. The maturity date of the Line of Credit Agreement was June 17, 2022, and the amounts due on that date were not paid. The Company is in discussions with Cornerstone Pharmaceuticals and is evaluating its rights and plan of action with respect to the Line of Credit Agreement (in the contexts of all of its interests in Cornerstone Pharmaceuticals). Due to the Data Events, the Company recorded a full reserve on the amounts due the Company from Cornerstone Pharmaceuticals related to the Line of Credit Agreement for $25 million during the year ended July 31, 2022. The Company also recorded a loss on related party receivables of approximately $2.6 million related to other amounts owed by Cornerstone Pharmaceuticals during the year ended July 31, 2022. The Company recorded a reserve on related party interest receivable of $1.9 million in Interest income, net, on the consolidated statements of operations and comprehensive loss during the year ended July 31, 2022. There were no amounts recorded during the year ended July 31, 2023. Planned Restructuring Cornerstone is in the process of a comprehensive restructuring transaction including, the conversion of the debt under the Line of Credit Agreement and the Promissory Note held by the Company, the conversion and modification of other Cornerstone debt obligations, the extension of the Cornerstone debt held by RP Finance, a reverse stock split, the conversion of all outstanding preferred stock of Cornerstone into common stock and the adoption of certain governance measures. This transaction is subject to a number of conditions which are beyond the Company’s control.

Convertible Note Receivable, Re

Convertible Note Receivable, Related Party	12 Months Ended
	Jul. 31, 2023
Convertible Note Receivable, Related Party [Abstract]
CONVERTIBLE NOTE RECEIVABLE, RELATED PARTY	NOTE 5 – CONVERTIBLE NOTE RECEIVABLE, RELATED PARTY On March 21, 2023, the Company loaned $2.0 million to Cornerstone which is represented by a Promissory Note (the “Promissory Note” or “Note”) made by Cornerstone. The Note, which bears interest at a rate of seven and one-half percent (7.5%) per annum, was originally due and payable on May 22, 2023. On May 22, 2023, the Promissory Note was amended to extend the maturity date to November 30, 2023 and to waive any increase in the interest rate provided for in the Note, provided that the entire principal amount and all accrued interest thereon is repaid in cash or converted into equity securities of Cornerstone no later than November 30, 2023. The Promissory Note is secured by a first priority security interest in all of Cornerstone’s right, title and interest in and to all of the tangible and intangible assets purchased by Cornerstone pursuant to the Purchase Agreement between Cornerstone and Calithera Biosciences, Inc. (“Calithera”), a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations, and all proceeds therefrom and all rights to the data related to CB-839 (the “Collateral”). The interest on the Promissory Note accrues from the issuance date until the Note is paid in full or converted, which shall accrue on a quarterly basis. Subject to the amendment described above, in the event the total outstanding amount under the Promissory Note is not repaid by the amended maturity date, the rate of interest shall be eleven percent (11%), retroactive from and after the maturity date. Subject to the amendment described above, following the occurrence of and during the continuation of an uncured Event of Default (as defined below), the outstanding principal amount shall bear interest at the rate of fourteen percent (14%) per annum (the “Default Interest Rate”) until the earliest of (i) cure of such Event of Default, (ii) repayment of all outstanding amounts due under the Note, (iii) conversion of all then outstanding obligations under the Note, or (iv) transfer of all its rights related to the Collateral. The entire (and not less than the entire) outstanding principal amount due under the Promissory Note together with all accrued unpaid interest thereon and other amounts owing thereunder (together, the “Owed Amount”), may, at Cornerstone’s election at any time prior to the maturity date, be converted into a number of shares (the “Conversion Shares”) calculated by dividing the entire Owed Amount by the conversion price used by Cornerstone in a Qualified Offering/Conversion (as defined in the Note), and if no such Qualified Offering/Conversion has been consummated, the fair market value for the Conversion as determined by an independent third party valuation firm (the “Conversion Price”). The Promissory Note contains certain trigger events (as defined in the Note) that generally, if uncured within five (5) trading days, may result in an event of default in accordance with the terms of the Notes (such event, an “Event of Default”). Upon an Event of a Default, the Company may consider the Promissory Note immediately due and payable. Upon an Event of Default, the interest rate may also be increased to the lesser of 18% per annum or the maximum rate permitted under applicable law. The Company recorded the Promissory Note at fair value as the security is classified as available-for-sale. Subsequent changes in fair value are recorded in unrealized gain or loss on available-for-sale securities as a component of other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. For the year ended July 31, 2023, the Company recorded a change in fair value of approximately $79 thousand related to the decrease in fair value of the Promissory Note which was recognized in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Interest income on the Promissory Note totaled approximately $54 thousand for the year ended July 31, 2023 and is recorded in interest receivable on the consolidated balance sheets.

Investment in RP Finance, LLC

Investment in RP Finance, LLC	12 Months Ended
	Jul. 31, 2023
Investment in RP Finance, LLC [Abstract]
INVESTMENT IN RP FINANCE, LLC	NOTE 6 – INVESTMENT IN RP FINANCE, LLC On February 3, 2020, Cornerstone Pharmaceuticals entered into a Line of Credit with RP Finance (“RPF Line of Credit”) which provides a revolving commitment of up to $50,000,000 to fund clinical trials and other capital needs. The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. The Instrument owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. The remaining 25% equity interests in RP Finance are owned by other stockholders of Cornerstone Pharmaceuticals. Under the RPF Line of Credit, all funds borrowed will bear interest at the mid-term Applicable Federal Rate published by the U.S. Internal Revenue Service. The maturity date is the earliest of February 3, 2025, upon a change of control of Cornerstone Pharmaceuticals or a sale of Cornerstone Pharmaceuticals or its assets. Cornerstone Pharmaceuticals can draw on the facility on 60 days’ notice. The funds borrowed under the RPF Line of Credit must be repaid out of certain proceeds from equity sales by Cornerstone Pharmaceuticals. In connection with entering into the RPF Line of Credit, Cornerstone Pharmaceuticals agreed to issue to RP Finance shares of its common stock representing 12% of the issued and outstanding shares of Cornerstone Pharmaceuticals common stock, with such interest subject to anti-dilution protection as set forth in the RPF Line of Credit. The Company has determined that RP Finance is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. Therefore, the Company will use the equity method of accounting to record its investment in RP Finance. The Company has recognized $0 in earnings from its ownership interests of 37.5% in RP Finance for the years ended July 31, 2023 and 2022, respectively, and a loss of $0 and $575 thousand from its ownership interests of 37.5% in RP Finance for the years ended July 31, 2023 and 2022, respectively. The assets and operations of RP Finance are not significant and the Company has identified the equity investment in RP Finance as a related party transaction (see Note 16). In August 2020, Cornerstone Pharmaceuticals called for a $5 million draw on the RPF Line of Credit and the facility was funded by RP Finance in the amount of $5 million. In November 2020, Cornerstone Pharmaceuticals called for a second $5 million draw on the RPF Line of Credit and the facility was funded by RP Finance in the amount of $5 million. In June 2021 and July 2021, Cornerstone Pharmaceuticals called for a total aggregate of $10 million in draws on the line of RPF Line of Credit and the facility was funded by RP Finance in the amount of $10 million. In September 2021, Cornerstone Pharmaceuticals called for a $5 million draw on the RPF Line of Credit and the facility was funded by RP Finance LLC in the amount of $5 million. As of July 31, 2023 and 2022, the Company has funded a cumulative total of $9.375 million in accordance with its 37.5% ownership interests in RP Finance. The Company recorded a reserve on related party interest receivable of $1.9 million in Interest income, net, on the consolidated statements of operations and comprehensive loss during the year ended July 31, 2022. Impairment of Equity Method Investment Due to the Data Events, during the three months ended October 31, 2021, the Company recorded equity in the loss of RP Finance of $575 thousand. As of July 31, 2023 and 2022, the equity method investment on the Company’s balance sheet was $0, and no additional equity loss of RP Finance was recorded during the year ended July 31, 2023. The Company was not obligated to guarantee obligations of RP Finance and is not committed to provided further financial support for RP Finance. Additionally, during the year ended July 31, 2022, the Company recorded a loss on related party receivables of $9.375 million related to amounts owed by RP Finance.

Investment in LipoMedix Pharmac

Investment in LipoMedix Pharmaceuticals Ltd	12 Months Ended
	Jul. 31, 2023
Investment in LipoMedix Pharmaceuticals Ltd [Abstract]
INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD	NOTE 7 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD. LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. As of July 31, 2023, the Company held 95% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018. In March 2021, the Company provided bridge financing in the principal amount of up to $400,000 to LipoMedix with a maturity date of September 1, 2021, and an interest rate of 8% per annum. As of September 1, 2021, LipoMedix was in default on the terms of the loan and as such, the interest rate has increased to 15% per annum. On November 15, 2021, the Company entered into a share purchase agreement with LipoMedix to purchase up to 15,975,000 ordinary shares at $0.1878 per share for an aggregate purchase price of $3.0 million (the “LipoMedix SPA”). Additionally, LipoMedix issued the Company a warrant to purchase up to 15,975,000 ordinary shares at an exercise price of $0.1878 per share which expired on November 11, 2022. As of the date of the LipoMedix SPA, there was an outstanding loan balance including principal of $400 thousand and accrued interest of $21.8 thousand owed by LipoMedix to the Company on a note made by LipoMedix in favor of the Company issued in March 2021. The amount due on the loan was netted against the approximately $3.0 million aggregate purchase price due to LipoMedix, resulting in a cash payment by the Company of approximately $2.6 million in exchange for the 15,975,000 shares purchased. As a result of the share purchase, the Company’s ownership of LipoMedix increased to approximately 84% with a noncontrolling interest of approximately 16%. The Company recorded approximately $8 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company’s increased ownership interest in LipoMedix’s net assets. On February 9, 2023, the Company entered into a Share Purchase Agreement with LipoMedix to purchase 70,000,000 ordinary shares at $0.03 per share for an aggregate purchase price of $2.1 million (the “2023 LipoMedix SPA”). As a result of the share purchase, the Company’s ownership of LipoMedix increased to approximately 95% with a noncontrolling interest of approximately 5%. The Company recorded approximately $16 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company’s increased ownership interest in LipoMedix’s net assets.

Investment in Day Three Labs In

Investment in Day Three Labs Inc.	12 Months Ended
	Jul. 31, 2023
Investment in Day Three Labs Inc. [Abstract]
INVESTMENT IN DAY THREE LABS INC.	NOTE 8 – INVESTMENT IN DAY THREE LABS INC. On April 7, 2023, the Company entered into a Common Stock Purchase Agreement (the “Day Three Purchase Agreement”) with Day Three. Day Three is a cannabinoid ingredient manufacturer specializing in the development and commercialization of novel cannabis product solutions. Pursuant to the Day Three Purchase Agreement, the Company purchased 4,302,224 shares of common stock representing 38% of the outstanding shares of common stock of Day Three (33.333% on a fully diluted basis), for a purchase price of $3.0 million. The Company also received a warrant exercisable for 7,528,893 shares of common stock at an aggregate purchase price of $3.0 million, which expires five years from the date of issuance or earlier based on the occurrence of certain events as defined in the Day Three Purchase Agreement. As of the date of this report, the Company had not exercised the warrant. The Company has accounted for this investment as an equity method investment in accordance with the guidance in ASC 323, Investments – Equity Method and Joint Ventures The Company has determined that Day Three is a VIE; however, the Company is not the primary beneficiary as it does not have the power to direct the activities that most significantly impact Day Three’s economic performance. The Company has therefore concluded it is not required to consolidate Day Three. The Company uses the equity method of accounting to record its investment in Day Three. Day Three’s fiscal year ends on December 31, and as a result, the Company will recognize its share of Day Three’s earnings/loss on a one-month lag. For the year ended July 31, 2023, the Company recognized approximately $203 thousand of equity in loss of Day Three, based on its proportionate share of Day Three’s results through June 30, 2023. The assets and operations of Day Three are not significant.

Investment in Cyclo Therapeutic

Investment in Cyclo Therapeutics, Inc.	12 Months Ended
	Jul. 31, 2023
Investment in Cyclo Therapeutics, Inc. [Abstract]
INVESTMENT IN CYCLO THERAPEUTICS, INC.	NOTE 9 – INVESTMENT IN CYCLO THERAPEUTICS, INC. On May 2, 2023, the Company entered into a Securities Purchase Agreement (the “Cyclo SPA”) with Cyclo. Cyclo is a clinical stage biotechnology company, whose common stock is listed on the Nasdaq Capital Market under the symbol CYTH, that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. The Company purchased from Cyclo (i) 2,514,970 common shares (the “Purchased Shares”) and (ii) a warrant to purchase 2,514,970 common shares with an exercise price of $0.71 per share (the “Cyclo Warrant”), at a combined purchase price equal to $0.835 per Purchased Share and Cyclo Warrant to purchase one share, for an aggregate purchase price of $2.1 million. The Cyclo Warrant may be exercised for the seven-year period following the date Cyclo obtains the approval of the stockholders of Cyclo to the exercise of the Cyclo Warrant. On July 31, 2023, the Cyclo stockholders approved the exercise in full of the warrant. On June 1, 2023, the Company entered into another Securities Purchase Agreement (the “Cyclo II SPA”) with Cyclo. Pursuant to the Cyclo II SPA, the Company agreed to purchase an additional 4,000,000 shares of common stock (the “Cyclo II Shares”), and a warrant to purchase an additional 4,000,000 Shares (the “Cyclo II Warrant”), for an aggregate purchase price of $5,000,000. The Cyclo II Warrant has an exercise price of $1.25 per share and is exercisable for a period of seven years following the date of issuance. On July 31, 2023, Cyclo obtained the approval of its stockholders for the transactions contemplated by the Cyclo II SPA. Subsequent to year end, on August 1, 2023, the Company completed the Cyclo II SPA with Cyclo, whereby the Company purchased 4,000,000 shares of common stock (the “Cyclo II Shares”), and a warrant to purchase an additional 4,000,000 Shares (the “Cyclo II Warrant”), for an aggregate purchase price of $5,000,000. The August 1, 2023 investment increased the Company’s percentage ownership of Cyclo common stock to 34%. As of the date of this report, the Company had not exercised the Cyclo II Warrant. Pursuant to the Cyclo II SPA, the Registration Rights Agreement between the Company and Cyclo, dated May 2, 2023, has been amended to require Cyclo to file a registration statement with the Securities and Exchange Commission to register the resale of the Cyclo II Shares and shares of common stock underlying the Cyclo II Warrants, upon the request of the Company, and (ii) Cyclo agreed to appoint a designee of the Company (in addition to William Conkling, the Company’s Chief Executive Officer) to Cyclo’s Board of Directors, and to nominate such designee to serve as a director of Cyclo in connection with Cyclo’s solicitation of proxies for Cyclo’s next Annual Meeting of Stockholders. The Cyclo II SPA purchase price was paid on August 1, 2023, which is the effective date of the second Cyclo investment. Subsequent to year end, on October 20, 2023, the Company exercised the Cyclo Warrant to purchase 2,514,970 common shares at an exercise price of $0.71 per share, pursuant to a Securities Purchase Agreement dated October 20, 2023, and in consideration received a new warrant to purchase an additional 2,766,467 common shares at an exercise price of $0.95 per share which are exercisable for a period of four years following the issuance date (the “Cyclo III Warrant”), for an aggregate purchase price of $1,785,629. The Company has elected to account for its investment in Cyclo under the fair value option. The investment was measured at fair value and the Company has recorded the subsequent changes in fair value as unrealized gain (loss) in the consolidated statements of operations and comprehensive loss. The investment in the Cyclo SPA resulted in an unrealized gain of approximately $2.1 million as the purchase price was lower than the fair value of the investment. The Company recognized total unrealized gains on its investment of $2.7 million in the accompanying consolidated statements of operations and comprehensive loss for the year ended July 31, 2023. Summarized Fair Value (Level 1) Method Investment Details Ownership % Aggregate Fair Value July 31, July 31, Cyclo 16 % $ 4,763,102 The 16% ownership percentage as of July 31, 2023 is comprised of the shares of common stock owned by the Company and does not include the Cyclo Warrant. The total aggregate fair value of the Cyclo investment of $4,763,102 as of July 31, 2023 is comprised of common shares with an aggregate fair value of $3,898,204 and warrants with an aggregate fair value of $864,898. Summarized consolidated financial information of Cyclo, reported on a one month lag, is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Revenue $ 117,118 $ 541,886 $ 269,529 $ 736,790 Loss from operations $ (4,632,942 ) $ (3,456,024 ) $ (9,640,074 ) $ (6,390,481 ) Net loss $ (4,636,455 ) $ (3,451,990 ) $ (9,643,540 ) $ (6,223,581 )

Investment

Investment	12 Months Ended
	Jul. 31, 2023
Investment [Abstract]
INVESTMENTS	NOTE 10 – INVESTMENTS The Company has classified its investments in corporate bonds, U.S. treasury bills, and convertible note receivable as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders’ equity until realized. Investment transactions are recorded on their trade date. Gains and losses on marketable security transactions are reported on the specific-identification method. Interest income is accrued daily and adjusted for amortization of premiums and accretion of discounts on the corporate bonds and U.S. treasury bills. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities as of July 31, 2023 and 2022 are as follows: July 31, 2023 Amortized Gross Gross Fair value (in thousands) Available-for-sale securities: U.S. Treasury Bills $ 11,222 $ 53 $ — $ 11,275 Corporate bonds 46,766 4,333 (4,660 ) 46,439 Convertible note receivable, related party 2,000 — (79 ) 1,921 Total available-for-sale securities $ 59,988 $ 4,386 $ (4,739 ) $ 59,635 July 31, 2022 Amortized cost Gross Gross Fair value (in thousands) Available-for-sale securities: Corporate bonds $ 36,761 $ 81 $ (144 ) $ 36,698 Total available-for-sale securities $ 36,761 $ 81 $ (144 ) $ 36,698 During the year ended July 31, 2023, the Company reclassified approximately $154 thousand of unrealized gains out of accumulated other comprehensive loss related to the sale of available-for-sale securities into consolidated net loss in the consolidated statements of operations and comprehensive loss in realized gain on available-for-sale securities. Maturities of corporate bonds and U.S. Treasury Bills held as of July 31, 2023 were all due within one Marketable securities in an unrealized loss position as of July 31, 2023 were not deemed impaired at acquisition and subsequent declines in fair value are not deemed attributed to declines in credit quality. The Company believes that it is more likely than not that it will receive a full recovery of par value on the securities, although there can be no assurance that such recovery will occur.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jul. 31, 2023
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: ● Level 1 ● Level 2 ● Level 3 The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of July 31, 2023 and 2022: July 31, 2023 Level 1 Level 2 Level 3 Total (in thousands) Assets: Available-for-sale securities - Corporate Bonds $ — $ 46,439 $ — $ 46,439 Available-for-sale securities - U.S. Treasury Bills 11,275 — — 11,275 Investment in equity securities 294 — — 294 Investment in Cyclo Therapeutics Inc. - Common stock 3,898 — — 3,898 Investment in Cyclo Therapeutics Inc. - Warrants 865 — — 865 Hedge funds — — 4,984 4,984 Convertible note receivable, related party — — 1,921 1,921 Total $ 16,332 $ 46,439 $ 6,905 $ 69,676 July 31, 2022 Level 1 Level 2 Level 3 Total (in thousands) Assets: Available-for-sale securities - Corporate Bonds $ — $ 36,698 $ — $ 36,698 Hedge funds — — 4,764 4,764 Total $ — $ 36,698 $ 4,764 $ 41,462 As of July 31, 2023 and 2022, the Company did not have any liabilities measured at fair value on a recurring basis. The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3): Year Ended July 31, 2023 2022 (in thousands) Balance, beginning of period $ 4,764 $ 5,268 Total gain (loss) included in earnings 220 (504 ) Convertible note receivable, related party 2,000 — Total loss included in other comprehensive loss (79 ) — Balance, end of period $ 6,905 $ 4,764 Hedge funds classified as Level 3 include investments and securities which may not be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets is estimated based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. Available-for-sale securities classified as Level 3 include a convertible note receivable, related party (see Note 5) which may not be based on readily observable data inputs. The availability of observable inputs can vary and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of this asset is estimated using a scenario-based analysis based on the probability-weighted present value of future investments returns, considering each of the possible outcomes available to us, including cash repayment, equity conversion, and collateral transfer scenarios. Estimating the fair value of the convertible note requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Therefore, this asset is classified as Level 3. The Company holds $0.1 and $0.5 million as of July 31, 2023 and 2022, respectively, in investments in securities in another entity that are not liquid, which were included in Investments - Other Pharmaceuticals in the accompanying consolidated balance sheets. The investment is accounted for under ASC 321, Investments - Equity Securities Fair Value of Other Financial Instruments The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The Company’s financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amounts of accounts receivable, accounts payable and due to related parties approximate their fair value due to their short-term nature.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Jul. 31, 2023
Accounts Receivable [Abstract]
ACCOUNTS RECEIVABLE	NOTE 12 – ACCOUNTS RECEIVABLE Accounts receivable consisted of the following: July 31, July 31, (in thousands) Accounts Receivable - Third Party $ 247 $ 196 Accounts Receivable - Related Party 211 158 Less Allowance for Doubtful Accounts (245 ) (197 ) Accounts Receivable, net $ 213 $ 157

Property and Equipment

Property and Equipment	12 Months Ended
	Jul. 31, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 13 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: July 31, July 31, 2023 2022 (in thousands) Building and Improvements $ 2,505 $ 2,505 Other 68 68 2,573 2,573 Less Accumulated Depreciation (878 ) (803 ) Total $ 1,695 $ 1,770 Other property and equipment consist of other equipment and miscellaneous computer hardware. Depreciation expense pertaining to property and equipment was approximately $78 thousand and $72 thousand for the years ended July 31, 2023 and 2022, respectively. The Company’s headquarters are located at 520 Broad Street in Newark, New Jersey, where it occupies office space and which was previously owned by the Company. The table above excludes the assets of the 520 Property which were classified as held-for-sale as of July 31, 2022 and subsequently sold on August 22, 2022. Refer to Note 3 for further information on the 520 Property.

Loss Per Share

Loss Per Share	12 Months Ended
	Jul. 31, 2023
Loss Per Share [Abstract]
LOSS PER SHARE	NOTE 14 – LOSS PER SHARE Basic loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per share includes potentially dilutive securities such as stock options, unvested restricted stock, warrants to purchase common stock, and other convertible instruments unless the result of inclusion would be anti-dilutive. The securities set forth in the table below have been excluded from the calculation of diluted net loss per share for the years ended July 31, 2023 and 2022 because inclusion of all such securities would have been anti-dilutive for all periods presented. The following table summarizes the Company’s potentially dilutive securities which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: Year Ended July 31, 2023 2022 Shares issuable upon exercise of stock options 388,409 1,021,277 Shares issuable upon vesting of restricted stock 684,766 1,507,373 1,073,175 2,528,650 The diluted loss per share computation equals basic loss per share for the years ended July 31, 2023 and 2022 because the Company had a net loss from continuing operations in all such periods and the impact of the assumed vesting of restricted shares, and exercise of stock options, and warrants would have been anti-dilutive. The following table summarizes the basic and diluted loss per share calculations (in thousands, except for share and per share amounts): Year Ended July 31, 2023 2022 Numerator: Net loss from continuing operations $ (8,693 ) $ (140,547 ) Net loss attributable to noncontrolling interests (339 ) (17,719 ) Numerator for net loss from continuing operations (8,354 ) (122,828 ) Numerator for discontinued operations 6,478 (1,830 ) Net loss attributable to Rafael Holdings, Inc. $ (1,876 ) $ (124,658 ) Denominator: Weighted average basic and diluted shares outstanding 23,263,211 19,767,342 Loss per share attributable to common stockholders Basic and diluted: Continuing operations $ (0.36 ) $ (6.22 ) Discontinued operations 0.28 (0.09 ) Total basic and diluted loss per share $ (0.08 ) $ (6.31 )

Note Payable, Held-For-Sale

Note Payable, Held-For-Sale	12 Months Ended
	Jul. 31, 2023
Note Payable, Held-For-Sale [Abstract]
NOTE PAYABLE, HELD-FOR-SALE	NOTE 15 – NOTE PAYABLE, HELD-FOR-SALE On July 9, 2021, the Company, as guarantor, Rafael Holdings Realty, Inc., a wholly-owned subsidiary of the Company (“Realty”), as pledgor, and Broad-Atlantic, a wholly-owned subsidiary of Realty (the “Borrower,” and together with the Company and Realty, the “Borrower Parties”), as borrower, entered into a loan agreement (the “Loan Agreement”) with 520 Broad Street LLC, a third-party lender (the “Lender”). The Loan Agreement provided for a loan in the amount of $15 million (the “Note Payable”) from Lender to Borrower secured by (i) a first mortgage on 520 Broad Street, Newark, New Jersey 07102; and (ii) a first priority security interest in the equity of the Borrower as set forth in the Pledge and Security Agreement between Realty and Lender. The Note Payable bore interest at a rate per annum equal to seven and one-quarter percent (7.25%) from July 9, 2021 through July 31, 2021 and thereafter at an interest rate per annum equal to the 30-day LIBOR Rate, as published in The Wall Street Journal The Loan Agreement contained customary affirmative covenants, negative covenants and events of default, as defined in the Loan Agreement, including covenants and restrictions that, among other things, restricted the Borrower’s ability to incur liens, or transfer, lease or sell the collateral as defined in the Loan Agreement. A failure to comply with these covenants would have permitted the Lender to declare the Borrower’s obligations under the Loan Agreement, together with accrued interest and fees, to be immediately due and payable. The Company was in compli In connection with the sale of the 520 Property, on August 22, 2022, the Company paid off the outstanding principal balance of $15 million and accrued interest of approximately $87,000 on the Note Payable. Refer to Note 3 for further details on the subsequent sale of the 520 Property. Interest expense under the Note Payable, which is recognized in loss on discontinued operations, amounted to $87 thousand for the year ended July 31, 2023, and $1.2 million for the year ended July 31, 2022. Unamortized debt issuance costs on the Note Payable totaled approximately $0 as of July 31, 2023 and 2022. Amortization of the debt discount on the Note Payable totaled approximately $0 and $472 thousand for the years ended July 31, 2023 and 2022, respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jul. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 16 – RELATED PARTY TRANSACTIONS IDT Corporation The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT and payroll costs for the Company’s personnel that were paid by IDT. IDT billed the Company approximately $313 thousand and $343 thousand for services during the years ended July 31, 2023 and 2022, respectively, of which $70 thousand and $69 thousand is included in due to related parties at July 31, 2023 and 2022, respectively. IDT leased, prior to the Company’s sale of the property, approximately 80,000 square feet of office space plus parking at the 520 Property and leases approximately 3,600 square feet of office space in Jerusalem, Israel. The Company invoiced IDT approximately $211 thousand, of which approximately $102 thousand is included in discontinued operations during the year ended July 31, 2023. The Company invoiced IDT approximately $2.1 million, of which approximately $2.0 million is included in discontinued operations for office rent and parking during the year ended July 31, 2022. As of July 31, 2023 and 2022, IDT owed the Company approximately $210 thousand and $157 thousand, respectively, for office rent and parking. Cornerstone Pharmaceuticals Until October 31, 2021, the Company had provided Cornerstone Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas and William Conkling currently serve on the Board of Directors of Cornerstone Pharmaceuticals. The Company billed Cornerstone Pharmaceuticals $120 thousand for the year ended July 31, 2022. As of July 31, 2023 and July 31, 2022, Cornerstone Pharmaceuticals owed the Company $720 thousand, for which a full allowance for uncollectibility has been recorded. Due to the Data Events, in the year ended July 31, 2022, the balance owed to the Company by Cornerstone Pharmaceuticals was fully reserved, resulting in a loss on related party receivable of $720 thousand (see Note 4). On March 21, 2023, the Company entered into a Promissory Note with Cornerstone Pharmaceuticals, wherein, Cornerstone Pharmaceuticals promises to pay the Company $2 million together with all interest accrued on May 22, 2023, or such earlier date as the Promissory Note is required or permitted to be repaid (see Note 5). On May 22, 2023, the Promissory Note was amended to extend the maturity date to November 30, 2023 and to waive the interest increase (see Note 5). Genie Energy, Ltd. The Company leased office space at 520 Broad Street to Genie. The Company invoiced Genie approximately $19 thousand which is included in discontinued operations during the year ended July 31, 2023. Genie pays the Company for payroll costs for certain personnel which totaled approximately $10 thousand during the year ended July 31, 2023. Related Party Rental Income The Company leased space to related parties (including IDT Corporation - see above) which represented approximately 42% and 58% of the Company’s total revenue for the years ended July 31, 2023 and 2022, respectively. The portion of related party rental income pertaining to the 520 Property has been classified in discontinued operations on the consolidated statements of operations and comprehensive loss for the years ended July 31, 2023 and 2022. RP Finance For the year ended July 31, 2023, the Company recognized $0 from its ownership interests of 37.5% in RP Finance. For the year ended July 31, 2022, the Company recognized a loss of $575 thousand in income from its ownership interests of 37.5% in RP Finance. Howard Jonas, Chairman of the Board and Former Chief Executive Officer In December 2020, IDT Corporation and Genie Energy Ltd, on whose Boards of Directors Howard Jonas, the Company’s Chairman of the Board and Executive Chairman and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. In connection with the purchases, each purchaser was granted warrants (the “Issued Warrants”) to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Issued Warrants have an exercise price of $22.91 per share and expired on June 6, 2022. The Issued Warrants were not exercised. The shares and Issued Warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. On June 22, 2022, the Company entered into a Stock Purchase Agreement (the “I9 SPA”) with I9 Plus, LLC, an entity affiliated with members of the family of Howard Jonas. On July 6, 2022, pursuant to the I9 SPA, the Company sold 3,225,806 shares of the Company’s Class B common stock to I9 Plus, LLC at a price per share of $1.86 and an aggregate sale price of $6 million. On July 31, 2023, eight trusts, each for the benefit of a child of Howard S. Jonas, the Company’s Executive Chairman and Chairman of the Board, with independent trustees, transferred an aggregate of 787,163 shares of Class A common stock of the Company (representing all of the issued and outstanding shares of the Class A common stock of the Company, and 51.3% of the aggregate voting power of all issued and outstanding shares of capital stock of the Company) to a limited partnership. Howard Jonas is the sole manager of the sole general partner of the limited partnership, and, therefore, has sole voting and dispositive power over the shares of Class A common stock held by the limited partnership. Following the transfer, Mr. Jonas will be the controlling stockholder of the Company and the Company is a controlled company as defined in Section 303A of the New York Stock Exchange Listed Company Manual. LipoMedix Pharmaceuticals, Ltd. As of the date of the LipoMedix SPA, on November 15, 2021, there was an outstanding loan balance including principal of $400 thousand and accrued interest of $21.8 thousand owed by LipoMedix to the Company on the note from March 2021. The amount due on the loan was netted against the $3.0 million aggregate purchase price due LipoMedix, resulting in a cash payment by the Company of approximately $2.6 million in exchange for the 15,975,000 shares purchased. As a result of the share purchase, the Company’s ownership of LipoMedix increased to approximately 84% with a noncontrolling interest of approximately 16%. On February 9, 2023, the Company entered into a share purchase agreement with LipoMedix to purchase 70,000,000 ordinary shares at $0.03 per share for an aggregate purchase price of $2.1 million. As a result of the share purchase, the Company’s ownership of LipoMedix increased to approximately 95% with a noncontrolling interest of approximately 5%. The Company recorded approximately $16 thousand to adjust the carrying amount of the noncontrolling interest to reflect the Company’s increased ownership interest in LipoMedix’s net assets. Investment in Equity Securities The Company entered into a Cooperation Agreement with Genie, IDT and trusts for the benefit of certain family members of Howard Jonas related to an investment in a third-party publicly traded company. Subsequently, the Company and Genie agreed to share the expenses related to the investment equally and each would retain any return from its own investments. The Company invested $1.6 million in the third-party company and after selling a portion of its interest made a profit of $309 thousand.

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 17 – INCOME TAXES At July 31, 2023, the Company had federal net operating loss (“NOL”) carryforwards from domestic operations of approximately $63.2 million, to offset future taxable income, state NOLs of $40.4 million, and NOLs from foreign operations of $7.6 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire. The components of loss from continuing operations before income taxes are as follows: For the Years Ended 2023 2022 (in thousands) Domestic $ (6,056 ) $ (137,978 ) Foreign (2,689 ) (1,994 ) Loss before income taxes $ (8,745 ) $ (139,972 ) Benefit from income taxes as presented in the consolidated statements of operations and comprehensive loss consisted of the following: For the Year Ended 2023 2022 (in thousands) Current: Foreign $ 19 $ — Federal — — State (274 ) — Total current expense (benefit) (255 ) — Deferred: Foreign — — Federal — — State — — Total deferred expense — — Benefit from income taxes $ (255 ) $ — The differences between income taxes expected at the U.S. federal statutory income tax rate attributable to pretax loss from continuing operations and income taxes attributable to pretax loss from continuing operations are reported as follows: At July 31, 2023 2022 (in thousands) U.S. federal income tax at statutory rate $ (1,877 ) $ (29,514 ) State income tax (479 ) (8,752 ) Valuation allowance 2,958 35,001 Foreign tax rate differential (583 ) (459 ) Tax law change — — Permanent differences — 3,632 Rate change — — Sale of state NOLs (274 ) - Other - 92 Benefit from income taxes $ (255 ) $ — During the year ended July 31, 2023, the Company received proceeds of approximately $274 thousand for the sale of the Company's 2018 and 2019 New Jersey tax credits through the New Jersey Technology Business Tax Certificate Transfer Program. The Company has not recorded U.S. income tax expense for foreign earnings because it has not generated any foreign earnings. Significant components of the Company’s deferred tax assets and deferred tax liabilities are as follows: At July 31, 2023 2022 (in thousands) Deferred tax assets: Net operating loss carryforwards $ 17,852 $ 15,170 Unrealized gain/loss 30,236 31,850 Depreciation (1 ) 1 R&D amortization 689 - Reserves and accruals 237 236 Stock-based compensation 1,858 1,839 Gross deferred tax assets 50,871 49,096 Less valuation allowance (50,871 ) (49,096 ) Total deferred tax assets — — Total deferred tax liabilities — — Deferred tax assets, net $ — $ —

Business Segment Information

Business Segment Information	12 Months Ended
	Jul. 31, 2023
Business Segment Information [Abstract]
BUSINESS SEGMENT INFORMATION	NOTE 18 – BUSINESS SEGMENT INFORMATION The Company conducts business as two operating segments, Healthcare and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s Chief Executive Officer who is the chief operating decision-maker. The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Healthcare segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on results of operations. The Healthcare segment is comprised of preferred and common equity interests and the Warrant to purchase equity interests in Cornerstone Pharmaceuticals, a majority equity interest in LipoMedix, Barer, Farber, and Rafael Medical Devices. To date, the Healthcare segment has not generated any revenues. The Real Estate segment consists of the Company’s real estate holdings, which is currently comprised of a portion of a commercial building in Israel. The revenue, (loss) income from operations, and (loss) income before taxes of the 520 Property have been excluded from the Real Estate segment in the figures below due to its classification of held-for-sale and discontinued operations, and the sale of the 520 Property on August 22, 2022. Operating results for the business segments of the Company are as follows: (in thousands) Healthcare Real Estate Total Year Ended July 31, 2023 Revenues $ — $ 279 $ 279 (Loss) income from operations (15,121 ) 78 (15,043 ) Year Ended July 31, 2022 Revenues $ — $ 410 $ 410 (Loss) income from operations (60,658 ) 181 (60,477 ) Geographic Information Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-U.S. customers as a percentage of total revenues, which are inclusive of revenue from discontinued operations, were as follows (revenues by country are determined based on the location of the related facility): Year Ended July 31, 2023 2022 Revenue from tenants located in Israel 53 % 7 % Net property, plant, and equipment and total assets held outside of the United States, which are located in Israel, were as follows: (in thousands) United States Israel Total July 31, 2023 Property, plant, and equipment, net $ 293 $ 1,402 $ 1,695 Total assets 95,244 3,585 98,829 July 31, 2022 Property, plant, and equipment, net $ 305 $ 1,465 $ 1,770 Total assets 114,053 4,267 118,320

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 19 – COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company’s results of operations, cash flows or financial condition. In December 2022, Broad Atlantic entered into a settlement agreement with a vendor providing for the payment by the Company of $113 thousand representing payment in full for repair work done on the premises prior to our sale of the 520 Property. This amount is included in discontinued operations on the consolidated statements of operations and comprehensive loss.

Equity

Equity	12 Months Ended
	Jul. 31, 2023
Equity [Abstract]
EQUITY	NOTE 20 – EQUITY Share Repurchase Program In April 2023, the Company’s Board of Directors approved a share repurchase program (the “2023 Share Repurchase Program”) authorizing the repurchase of up to $5 million of the Company’s Class B common stock. Under the 2023 Share Repurchase Program, which took effect on April 14, 2023, the Company may purchase its shares from time to time until the earlier of June 16, 2023 (the “Plan Termination Date”) or when $5 million worth of shares at $1.75 per share or below have been purchased. In July 2023, the 2023 Share Repurchase Program was amended to extend the Plan Termination Date to the earlier of July 1, 2024, or when $5 million worth of shares at $1.75 per share or below have been purchased. The timing and amount of any share repurchases under the 2023 Share Repurchase Program will be determined at the Company’s discretion and based on market conditions and other considerations. Share repurchases under the authorizations may be made through open market purchases or pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934. The program does not obligate the Company to acquire any particular amount of its Class B common stock, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. During the year ended July 31, 2023, the Company did not repurchase any of its Class B common stock. Class A Common Stock and Class B Common Stock The rights of holders of Class A common stock and Class B common stock are identical except for certain voting and conversion rights and restrictions on transferability. The holders of Class A common stock and Class B common stock receive identical dividends per share when and if declared by the Company’s Board of Directors. In addition, the holders of Class A common stock and Class B common stock have identical and equal priority rights per share in liquidation. The Class A common stock and Class B common stock do not have any other contractual participation rights. The holders of Class A common stock are entitled to three votes per share and the holders of Class B common stock are entitled to one-tenth of a vote per share. Each share of Class A common stock may be converted into one share of Class B common stock, at any time, at the option of the holder. Shares of Class A common stock are subject to certain limitations on transferability that do not apply to shares of Class B common stock. On May 27, 2021, the Company filed a Registration Statement on Form S-3, whereby the Company may sell up to $250 million of Class B common stock. This Registration Statement was declared effective on June 7, 2021. On June 1, 2021, the Company filed a Registration Statement on Form S-3 to issue 48,859 shares of Class B common stock for payment due on the purchase of Altira, an investment which has been subsequently fully impaired. On August 19, 2021, the Company entered into a Securities Purchase Agreement (the “Institutional Purchase Agreement”) with Institutional Investors and a Securities Purchase Agreement with I9Plus, LLC, (the “Jonas Purchase Agreement”), an entity affiliated with Howard S. Jonas, the Chairman of the Board of Directors of the Company. On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the “Institutional Shares”), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregate gross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses. Additionally, pursuant to the Jonas Purchase Agreement, the Company issued 112,501 shares of Class B common stock to I9Plus, LLC, at a purchase price equal to $44.42 per share, which was equal to the closing price of a share of the Class B common stock on the New York Stock Exchange on August 19, 2021 (the “Jonas Offering”). The Jonas Offering resulted in additional aggregate gross proceeds of approximately $5.0 million. The total net proceeds from the issuance of shares was $98.0 million after deducting transaction costs of $6.2 million. On August 19, 2021, in connection with the Institutional Purchase Agreement, the Company entered into a Registration Rights Agreement with the Institutional Investors whereby the Company agreed to prepare and file a registration statement with the SEC within 30 days after the earlier of (i) the date of the closing of the Merger Agreement, and (ii) the date the Merger Agreement is terminated in accordance with its terms, for purposes of registering the resale of the Institutional Shares and any shares of Class B common stock issued as a dividend or other distribution with respect to the Institutional Shares. The 2018 Equity Incentive Plan was created and adopted by the Company in March 2018. On January 19, 2022, the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”). The 2018 Equity Incentive Plan was suspended and replaced by the 2021 Plan, and, following January 19, 2022, no new grants are to be awarded under the 2018 Equity Incentive Plan. Existing grants under the 2018 Equity Incentive Plan will not be impacted by the adoption of the 2021 Plan. Any of the Company’s employees, directors, consultants, and other service providers, and those of the Company’s affiliates, are eligible to participate in the 2021 Plan. In accordance with applicable tax rules, only employees (and the employees of parent or subsidiary corporations) are eligible to be granted incentive stock options. The 2021 Plan authorizes stock options (both incentive stock options or non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. On January 19, 2022, the Company filed a Registration Statement on Form S-8 registering 1,919,025 shares Class B Common Stock reserved for issuance under the 2021 Plan. On November 28, 2022, the Company’s Board of Directors approved an amendment to the 2021 Plan that, among other things, increases the number of shares of the Company’s Class B Common Stock available for the grant of awards thereunder by an additional 696,770, which the stockholders approved on January 23, 2023. The maximum number of shares of Class B common stock that may be issued under the 2021 Plan is 2,615,795 shares. As of July 31, 2023, there were 953,516 shares still available for issuance under the 2021 Plan. On February 15, 2022, the Company filed a Registration Statement on Form S-3 (as amended on March 2, 2022) registering the resale by institutional investors (the “Institutional Investors”) of the shares purchased by them. The Registration Statement was declared effective on March 7, 2022. On June 22, 2022, the Company entered into a Stock Purchase Agreement (the “I9 SPA”) with I9 Plus. On July 6, 2022, pursuant to the I9 SPA, the Company sold 3,225,806 shares of the Company’s Class B common stock to I9 Plus at a price per share of $1.86 and an aggregate sale price of $6 million, presented in common stock sold to related party within the statement of stockholders’ equity. The price per share was calculated to be the greater of (1) the volume weighted average price for the Class B common stock on the New York Stock Exchange for the five trading days ending on June 21, 2022 (which were the five trading days beginning with the first full trading day following the date that the transaction was approved by the Board of Directors of the Company, and its Corporate Governance Committee which consists solely of independent members of the Board) and (2) the closing price of the Class B common stock on June 21, 2022 (the trading day immediately preceding the date of the I9 SPA to ensure that the sale price was not below the Minimum Price under NYSE Rule 312.03(b)). The shares were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. Employment Agreement On June 13, 2022, the Company entered into an employment agreement with Howard S. Jonas (who serves as the Chairman of the Board and Executive Chairman of the Company) (the “Employment Agreement”), which provides, among other things: (i) a term of five years (subject to extension unless either party elects not to renew); (ii) an annual base salary of $260,000, of which $250,000 is payable through the issuance of restricted shares of the Company’s Class B common stock (“Class B Stock”) with the value of the shares based upon the volume weighted closing price of the Class B Stock on the NYSE on the thirty days ending with the NYSE trading day immediately preceding the issuance to be issued within thirty days of the date of the Employment Agreement (the “Start Date”) and each annual anniversary, and such shares vesting, contingent on Mr. Jonas’ remaining in continuous service to the Company, in substantially equal amounts on the three, six, nine and twelve month anniversaries of the Start Date or annual anniversary; and (iii) a grant of restricted shares of Class B stock with a value of $600,000, issuable within 30 days with the value of the shares based upon the volume weighted closing price of the Class B Stock on the NYSE on the thirty days ending with the NYSE trading day immediately preceding the issuance and such shares, and vesting, contingent on Mr. Jonas’ remaining in continuous service to the Company, in substantially equal amounts on the first and second annual anniversaries of the Start Date. Stock Options A summary of stock option activity for the Company is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding at July 31, 2021 683,414 $ 11.13 3.05 $ 26,982 Granted 518,304 20.54 9.25 — Cancelled / Forfeited (180,441 ) — — — Outstanding at July 31, 2022 1,021,277 12.11 4.47 — Granted 175,000 2.08 9.51 — Expired (589,205 ) — — — Cancelled / Forfeited (218,663 ) — — — Outstanding at July 31, 2023 388,409 $ 14.51 8.71 $ — Exercisable at July 31, 2023 65,456 $ 20.98 8.13 $ — At July 31, 2023, there is unrecognized compensation costs related to non-vested stock options of $1.3 million, which are expected to be recognized over the next 3.2 years. The value of option grants is calculated using the Black-Scholes option pricing model with the following assumptions for options granted during the years ended July 31, 2023 and 2022: For the Year Ended July 31, 2023 2022 Risk-free interest rate 3.60% - 3.66% 0.67% - 1.7% Expected term (in years) 6.11 6.04 - 6.11 Expected volatility 95.00% 75% - 93% Expected dividend yield —% —% The options granted had a $1.58 and $3.29 weighted average grant date fair value during the years ended July 31, 2023 and 2022, respectively. Rafael Medical Devices, Inc. Stock Options The Rafael Medical Devices, Inc. 2022 Equity Incentive Plan (the “RMD 2022 Plan”) was created and adopted by the Company in May 2022. The RMD 2022 Plan allows for the issuance of up to 10,000 shares of Class B common stock which may be awarded in the form of incentive stock options or restricted shares. There are 4,734 shares available for issuance under the RMD 2022 Plan as of July 31, 2023. The fair value of Rafael Medical Devices, LLC common stock was estimated for financial reporting purposes based on a valuation of $4.02 per share as of January 31, 2022. To determine the fair value of the common stock, the Company first determined an enterprise value using accepted valuation approaches; adjusted these valuation approaches with relevant discounts and then allocated the equity value to the common stock and common stock equivalents on a fully diluted basis. The enterprise value was estimated using the generally accepted income approach. The income approach estimates enterprise value based on the estimated present value of future cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate reflective of the risks associated with an investment in a similar company in a similar industry or having a similar history of revenue growth. The Company then subtracted the net non-operating assets and applied a discount for lack of marketability to determine equity fair value. A summary of stock option activity for Rafael Medical Devices, Inc. is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding at July 31, 2021 — $ — — $ — Granted 5,266 3.82 9.76 — Outstanding at July 31, 2022 5,266 $ 3.82 9.76 $ — Granted — — — — Outstanding at July 31, 2023 5,266 $ 3.82 8.76 — Exercisable at July 31, 2023 2,633 $ 3.82 8.76 $ — At July 31, 2023, there are unrecognized compensation costs related to non-vested stock options of $5 thousand, which are expected to be recognized over the next 1.44 years. Restricted Stock The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service. In January 2022, the Company granted 33,360 restricted shares of Class B common stock to non-employee directors, 18,336 of which were granted under the 2018 Equity Incentive Plan, and 15,024 of which were granted under the 2021 Plan. The restricted shares vested immediately on the grant date. The share based compensation cost was approximately $151 thousand, which was included in general and administrative expense in the consolidated statement of operations and comprehensive loss. On February 1, 2022, the Company issued 986,835 shares of Class B restricted stock to two members of the executive team. Approximately 24% of the restricted shares vest in December 2022, with the remaining shares vesting ratably each quarter through December 2025. On June 14, 2022, the Company issued 452,130 shares of Class B restricted stock to Howard S. Jonas. In January 2023, the Company issued 120,019 shares of Class B restricted stock to certain members of its Board of Directors, and 100,000 shares of Class B restricted stock to its new Chief Financial Officer. During January 2023, 296,759 shares of Class B restricted stock were cancelled or forfeited due to (i) the cancellation of 285,036 shares of restricted stock in connection with the departure of the Company’s former Chief Financial Officer and (ii) the remaining shares forfeited upon the termination of certain employees of the Company. In connection with Patrick Fabbio’s January 27, 2023 departure as the Company’s Chief Financial Officer, the Company and Mr. Fabbio entered into a Separation and General Release Agreement (the “Separation Agreement”), which provides, among other things, that the Company shall pay Mr. Fabbio severance in the amount of $307,913, which is included in selling, general and administrative expense on the consolidated statement of operations and comprehensive loss for the year ended July 31, 2023. In connection with the termination of Mr. Fabbio’s position as Chief Financial Officer of the Company, there was a material forfeiture of his Class B restricted shares and stock options resulting in a reversal of approximately $915 thousand in stock-based compensation expense for the year ended July 31, 2023 that was previously recorded to selling, general and administrative expense. A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below: Number of Non-vested Shares Weighted Average Grant Date Fair Value Outstanding at July 31, 2021 1,007,975 $ 46.77 Granted 1,533,311 4.24 Vested (90,608 ) 16.86 Cancelled / Forfeited (943,305 ) (48.50 ) Outstanding at July 31, 2022 1,507,373 $ 4.22 Granted 220,019 1.99 Vested (745,867 ) 3.37 Cancelled / Forfeited (296,759 ) (5.10 ) Non-vested shares at July 31, 2023 684,766 $ 4.04 At July 31, 2023, there was $1.8 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next four years. On November 21, 2021, Ameet Mallik resigned as Chief Executive Officer of the Company, effective January 31, 2022. In connection with his resignation, there was a material forfeiture of the former CEO’s Class B restricted shares, resulting in a reversal of approximately $19.0 million in stock-based compensation expense that was previously recorded to selling, general and administrative expense. Additionally, pursuant to the terms of his employment agreement, the Company paid $5.0 million relating to his severance payout, which is included in selling, general and administrative expense on the consolidated statement of operations and comprehensive loss for the year ended July 31, 2022. A summary of the stock-based compensation expense for the Company’s equity incentive plans is presented below (in thousands): For the Year Ended 2023 2022 General and administrative $ 3,044 $ 17,270 Research and development 194 791 Forfeiture of RSUs within general and administrative (931 ) (18,978 ) Forfeiture of RSUs within research and development (119 ) — Net stock-based compensation expense $ 2,188 $ (917 ) Securities Purchase Agreement On December 7, 2020, Rafael Holdings entered into a Securities Purchase Agreement (the “SPA”) for the sale of 567,437 shares of the Company’s Class B common stock at a price per share of $22.91 (which was the closing price for the Class B common stock on the New York Stock Exchange on December 4, 2020, the trading day immediately preceding the date of the SPA) for an aggregate purchase price of $13 million. Approximately $8.2 million of the proceeds received pursuant to the SPA were used by the Company to exercise an additional portion of the Warrant in order to maintain the Company’s relative position in Cornerstone Pharmaceuticals in light of issuances of Cornerstone Pharmaceuticals equity securities to third-party shareholders of Cornerstone Pharmaceuticals, due to warrant exercises by these shareholders. The Company is using the remaining proceeds to fund the operations of its drug development programs including its Barer Institute subsidiary, and for general corporate purposes. Under the SPA, two entities, on whose Boards of Directors Howard Jonas, the Registrant’s Chairman of the Board and former Chief Executive Officer serves, each purchased 218,245 shares of Class B common stock for consideration of $5 million each. The shares and warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. Equity-classified Warrants In connection with the SPA entered into on December 7, 2020, each purchaser was granted warrants to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The Company issued warrants to purchase 113,487 shares of Class B common stock to the purchasers. The warrants are exercisable at a per share exercise price of $22.91, and are exercisable at any time on or after December 7, 2020 through June 6, 2022. The Company determined that these warrants are equity-classified. During fiscal 2021, IDT and Genie each exercised 43,649 warrants, resulting in a total of 87,298 shares of Class B common stock issued for proceeds of approximately $2 million. On June 6, 2022, the Company’s outstanding warrants to purchase 26,189 shares of common stock at an exercise price of $22.91 per share expired. There were no exercises of warrants during the year ended July 31, 2022. At July 31, 2022, the Company had no outstanding warrants.

Leases

Leases	12 Months Ended
	Jul. 31, 2023
Leases [Abstract]
LEASES	NOTE 21 – LEASES The Company is the lessor of the Israeli property which is leased to tenants under net operating leases with a term expiration date within 2025. Lease income included on the consolidated statements of operations and comprehensive loss was $0.3 million and $0.3 million for the years ended July 31, 2023 and 2022, respectively. During the years ended July 31, 2023 and 2022, no real estate property taxes were included in rental income. The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of July 31, 2023, under non-cancellable operating leases which expire on various dates through 2025 are as follows: Year ending July 31, Related Parties Other Total (in thousands) 2024 $ 77 $ — $ 77 2025 78 — 78 Total Minimum Future Rental Income $ 155 $ — $ 155 A related party has the right to terminate the Israeli lease upon four months’ notice.

Subsequent Events

Subsequent Events	12 Months Ended
	Jul. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 22 – SUBSEQUENT EVENTS Issuance of Class B Common Stock On August 28, 2023, the Company granted 111,408 restricted shares of Class B common stock of the Company to Howard Jonas, the Chairman of the Board and Executive Chairman and former Chief Executive Officer of the Company and Member of the Board of Cornerstone Pharmaceuticals, pursuant to his employment agreement. Rafael Medical Devices, LLC outside party investment During the fourth quarter of the year ended July 31, 2023, the Company received $825 thousand as a deposit from outside third party investors for the purchase of membership units of Rafael Medical Devices, LLC. On August 1, 2023, the Company received an additional $100 thousand and closed on the sale of units in exchange of $925 thousand, whereby the Company will now hold 53.4% (on a fully diluted basis) ownership interests in Rafael Medical Devices, LLC. As of July 31, 2023, the Company recorded the funds received within prepaid expenses and other current assets and other current liabilities within the consolidated balance sheets.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jul. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal year 2023 refers to the fiscal year ended July 31, 2023). The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. GAAP. The accompanying consolidated financial statements reflect the activity related to the 520 Property as discontinued operations.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.
Liquidity	Liquidity As of July 31, 2023, the Company had cash and cash equivalents of approximately $21.5 million, and available-for-sale securities valued at approximately $57.7 million. On August 22, 2022, the Company received net proceeds of approximately $33 million in connection with the sale of the 520 Property (see Note 3 for further details). The Company expects the balance of cash and cash equivalents, and available-for-sale securities to be sufficient to meet its obligations for at least the next 12 months from the issuance of these consolidated financial statements.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For the year ended July 31, 2023, including revenue from discontinued operations, related parties represented 42% of the Company’s revenue. As of July 31, 2023, there were two customers which represented 27% and 47% of the Company’s accounts receivable balance. For the year ended July 31, 2022, including revenue from discontinued operations, related parties represented 58% of the Company’s revenue, and as of July 31, 2022, two customers, one of which is a related party, represented 24% and 47% of the Company’s accounts receivable balance, respectively.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Reserve for Receivables	Reserve for Receivables The Company evaluates accounts receivable, loans, interest and fees receivable for impairment under Accounting Standards Codification (“ASC”) 310, Receivables The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The allowance is determined based on known troubled accounts, historical experience and other currently available evidence. Doubtful accounts are written off upon final determination that the trade accounts will not be collected. The computation of this allowance is based on the tenants’ or parking customers’ payment histories, as well as certain industry or geographic specific credit considerations. If the Company’s estimates of collectability differ from the cash received, then the timing and amount of the Company’s reported revenue could be impacted. The credit risk is mitigated by the high quality of the Company’s existing tenant base, inclusive of related parties, which represented 42% and 58% of the Company’s total revenue for the years ended July 31, 2023 and 2022, respectively. The Company recorded bad debt expense of approximately $110 thousand and $4 thousand for the years ended July 31, 2023 and 2022, respectively.
Convertible Note Receivable, Related Party	Convertible Note Receivable, Related Party The Convertible Note Receivable is classified as available-for-sale as defined under ASC 320, Investments - Debt and Equity Securities The fair value of the Convertible Note Receivable is estimated using a scenario-based analysis based on the probability-weighted present value of future investment returns, considering each of the possible outcomes available to the Company, including cash repayment, equity conversion, and collateral transfer scenarios. Estimating the fair value of the convertible note requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors.
Variable Interest Entities	Variable Interest Entities In accordance with ASC 810, Consolidation If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.
Investments	Investments The method of accounting applied to long-term investments in equity securities involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also include the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated. Investments in equity securities may be accounted for using (i) the fair value option if elected, (ii) fair value through earnings if fair value is readily determinable or (iii) for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. The Company has elected the fair value option to account for its investment in Cyclo Therapeutics Inc. over which the Company has significant influence. The fair value option is irrevocable once elected. The Company measured its initial investment in Cyclo at fair value and shall record all subsequent changes in fair value in earnings in the consolidated statement of operations. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 9, “Investments.” Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for in accordance with ASC 321, Investments - Equity Securities
Investments - Hedge Funds	Investments - Hedge FundsThe Company accounts for its investments in hedge funds in accordance with ASC 321, Investments – Equity Securities. Unrealized gains and losses resulting from the change in fair value of these securities is included in unrealized (loss) gain on investments – Hedge Funds in the consolidated statements of operations and comprehensive loss.
Corporate Bonds and US Treasury Bills	Corporate Bonds and US Treasury Bills The Company’s marketable securities are considered to be available-for-sale as defined under ASC 320, Investments - Debt and Equity Securities
Cost Method Investment	Cost Method Investment The Company has determined that Cornerstone Pharmaceuticals (see Note 4) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Cornerstone Pharmaceuticals that most significantly impact Cornerstone Pharmaceuticals’ economic performance.
Equity Method Investments	Equity Method Investments The Company has determined that each of RP Finance, LLC (“RP Finance”) and Day Three Labs, Inc. (“Day Three”, RP Finance and Day Three, collectively, the “Equity Method Investees” and the Company’s investments in RP Finance and Day Three, collectively, the “Equity Method Investments”), (see Note 6 and Note 8), are each a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of the Equity Method Investees that most significantly impact the Equity Method Investees’ economic performance and, therefore, is not required to consolidate the Equity Method Investees. The Company accounts for the Equity Method Investments using the equity method of accounting.
Long-Lived Assets	Long-Lived Assets Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, which range as follows: Classification Years Building and improvements 40 Tenant improvements 7-15 Other (primarily equipment and furniture and fixtures) 5
Properties	Properties On August 22, 2022, Broad Atlantic Associates LLC, a wholly-owned subsidiary of the Company (“Broad Atlantic”), completed the sale of the 520 Property for a purchase price of $49.4 million. The 520 Property served as the Company’s headquarters and had several other tenants, and a related 800-car public parking garage. The Company determined that the 520 Property met the held-for-sale and discontinued operations criteria as of July 1, 2022. The 520 Property was disposed of on August 22, 2022. The Company owns a portion of the 6th floor of a building located at 5 Shlomo Halevi Street, in Jerusalem, Israel.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, which include property and equipment and in-process research and development and patents whenever significant events or changes in circumstances indicate that its carrying amount may not be recoverable. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a change to operating results. For the years ended July 31, 2023 and 2022, the Company determined that there was no impairment of its long-lived assets.
Assets Held-for-Sale and Discontinued Operations	Assets Held-for-Sale and Discontinued Operations The Company classifies assets as held-for-sale if all held-for-sale criteria are met pursuant to ASC 360-10, Property, Plant and Equipment Strategic changes in the Company’s operations can be considered a discontinued operation if both the operations and cash flows of the discontinued component have been (or will be) eliminated from the ongoing operations of the Company and the Company will not have any significant continuing involvement in the operations of the discontinued component after the disposal transaction. The results of the discontinued operations shall be reflected as a discontinued operation on the consolidated statements of operations and comprehensive loss and prior periods shall be recast to reflect the earnings from discontinued operations. As a result of the agreement to sell the 520 Property, the accompanying consolidated financial statements reflect the activity related to the sale of the 520 Property as discontinued operations. The Company determined that the 520 Property met the held-for-sale and discontinued operations criteria as of July 1, 2022. The 520 Property was disposed of on August 22, 2022. See Note 3 for additional information regarding the results, major classes of assets and liabilities, significant non-cash operating items, and capital expenditures of discontinued operations.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs are recorded net against the related debt and amortized to interest expense over the life of the related debt. During the years ended July 31, 2023 and 2022, amortized debt issuance costs of $0 and $472 thousand, respectively, were recorded as a component of interest expense which is included in Discontinued Operations.
Revenue Recognition	Revenue Recognition The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases The revenue derived from the 520 Property, which included leasing office and parking space to the tenants, is presented within discontinued operations in the consolidated statements of operations and comprehensive loss. Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earned revenue from parking which was derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and was accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.
Research and Development Costs	Research and Development Costs Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.
Repairs and Maintenance	Repairs and Maintenance The Company charges the cost of repairs and maintenance, including the cost of replacing minor items not constituting substantial betterment, to selling, general and administrative expenses as these costs are incurred.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the provisions of ASC 718, Stock-Based Compensation
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of such change. The Company uses a two-step approach for recognizing and measuring tax benefits taken or expected to be taken in a tax return. The Company determines whether it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, the Company presumes that the position will be examined by the appropriate taxing authority that has full knowledge of all relevant information. Tax positions that meet the more-likely-than-not recognition threshold are measured to determine the amount of tax benefit to recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Differences between tax positions taken in a tax return and amounts recognized in the financial statements will generally result in one or more of the following: an increase in a liability for income taxes payable, a reduction of an income tax refund receivable, a reduction in a deferred tax asset, or an increase in a deferred tax liability. The Company classifies interest and penalties on income taxes as a component of income tax expense, if any.
Contingencies	Contingencies The Company accrues for loss contingencies when both (a) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements and (b) the amount of loss can reasonably be estimated. When the Company accrues for loss contingencies and the reasonable estimate of the loss is within a range, the Company records its best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company discloses an estimated possible loss or a range of loss when it is at least reasonably possible that a loss may have been incurred.
Leases	Leases The Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays, that defer the commencement date of required payments. As of July 31, 2023 and 2022, the Company was not a lessee under any leasing arrangements.
Fair Value Measurements	Fair Value Measurements Fair value of financial and non-financial assets and liabilities is defined as an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three-tier hierarchy for inputs used to measure fair value, which prioritizes the inputs to valuation techniques used to measure fair value, is as follows: ● Level 1 - quoted prices in active markets for identical assets or liabilities; ● Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or ● Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy.
Functional Currency	Functional Currency The U.S. Dollar is the functional currency of our entities operating in the United States. The functional currency for our subsidiaries operating outside of the United States is the New Israeli Shekel, the currency of the primary economic environment in which such subsidiaries primarily expend cash. The Company translates those subsidiaries’ financial statements into U.S. Dollars. The Company translates assets and liabilities at the exchange rate in effect as of the consolidated financial statement date, and translates accounts from the consolidated statements of operations and comprehensive loss using the weighted average exchange rate for the period. The Company reports gains and losses from currency exchange rate changes related to intercompany receivables and payables, currently in non-operating expenses.
Loss Per Share	Loss Per Share Basic loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per share is determined in the same manner as basic loss per share, except that the number of shares is increased to include restricted stock still subject to risk of forfeiture and to assume exercise of potentially dilutive stock options using the treasury stock method, unless the effect of such increase would be anti-dilutive. The Company uses income from continuing operations as the “control number” or benchmark to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting earnings (loss) per share for discontinued operations.
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

Description of Business (Tables

Description of Business (Tables)	12 Months Ended
	Jul. 31, 2023
Description of Business [Abstract]
Schedule of All Majority-Owned Subsidiaries are Consolidated	All majority-owned subsidiaries are consolidated with all intercompany transactions and balances eliminated in consolidation. In addition to Rafael Holdings, Inc., the subsidiaries included in these consolidated financial statements are as follows: Company Country of Incorporation Percentage Owned Broad Atlantic Associates, LLC United States – Delaware 100 % IDT R.E. Holdings Ltd. Israel 100 % Rafael Holdings Realty, Inc. United States – Delaware 100 % Barer Institute, Inc. United States – Delaware 100 %* The Barer Institute, LLC United States – Delaware 100 %* Hillview Avenue Realty, JV United States – Delaware 100 % Hillview Avenue Realty, LLC United States – Delaware 100 % Rafael Medical Devices, Inc. United States – Delaware 100 % Levco Pharmaceuticals Ltd. Israel 95 %*** Farber Partners, LLC United States – Delaware 93 % Pharma Holdings, LLC United States – Delaware 90 % LipoMedix Pharmaceuticals Ltd. Israel 95 %**** Altira Capital & Consulting, LLC United States – Delaware 67 % CS Pharma Holdings, LLC United States – Delaware 45 %**

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jul. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Long-Lived Assets	Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, which range as follows: Classification Years Building and improvements 40 Tenant improvements 7-15 Other (primarily equipment and furniture and fixtures) 5

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Jul. 31, 2023
Discontinued Operations [Abstract]
Schedule of Classes of Assets and Liabilities	The carrying value of major classes of assets and liabilities related to discontinued operations at July 31, 2022 was as follows: As of (in thousands) Current assets held-for-sale Building and Improvements $ 45,437 Land 10,412 Furniture and Fixtures 1,145 Other 205 Property and equipment 57,199 Less Accumulated Depreciation (17,005 ) Property and equipment, net 40,194 Total current assets held-for-sale 40,194 Total assets held-for-sale $ 40,194 Current liabilities held-for-sale Total current liabilities $ 15,000
Schedule of Components Comprising Net Loss	The following table details the components comprising net loss from our discontinued operations: Year Ended July 31, 2023 2022 (in thousands) Revenue from discontinued operations: Rental – Third Party $ 68 $ 644 Rental – Related Party 115 2,161 Parking 66 694 Total revenue from discontinued operations 249 3,499 Costs and expenses from discontinued operations: General and administrative 468 2,683 Depreciation and amortization — 1,317 Loss from discontinued operations (219 ) (501 ) Other income — 157 Interest expense (87 ) (1,486 ) Loss from discontinued operations (306 ) (1,830 ) Gain on disposal of discontinued operations 6,784 — Gain (loss) from discontinued operations $ 6,478 $ (1,830 )

Investment in Cyclo Therapeut_2

Investment in Cyclo Therapeutics, Inc. (Tables)	12 Months Ended
	Jul. 31, 2023
Investment in Cyclo Therapeutics, Inc. [Abstract]
Schedule of Fair Value Method Investment	Summarized Fair Value (Level 1) Method Investment Details Ownership % Aggregate Fair Value July 31, July 31, Cyclo 16 % $ 4,763,102
Schedule of Consolidated Financial Information	Summarized consolidated financial information of Cyclo, reported on a one month lag, is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Revenue $ 117,118 $ 541,886 $ 269,529 $ 736,790 Loss from operations $ (4,632,942 ) $ (3,456,024 ) $ (9,640,074 ) $ (6,390,481 ) Net loss $ (4,636,455 ) $ (3,451,990 ) $ (9,643,540 ) $ (6,223,581 )

Investment (Tables)

Investment (Tables)	12 Months Ended
	Jul. 31, 2023
Investment [Abstract]
Schedule of Available-for-Sale Securities	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities as of July 31, 2023 and 2022 are as follows: July 31, 2023 Amortized Gross Gross Fair value (in thousands) Available-for-sale securities: U.S. Treasury Bills $ 11,222 $ 53 $ — $ 11,275 Corporate bonds 46,766 4,333 (4,660 ) 46,439 Convertible note receivable, related party 2,000 — (79 ) 1,921 Total available-for-sale securities $ 59,988 $ 4,386 $ (4,739 ) $ 59,635 July 31, 2022 Amortized cost Gross Gross Fair value (in thousands) Available-for-sale securities: Corporate bonds $ 36,761 $ 81 $ (144 ) $ 36,698 Total available-for-sale securities $ 36,761 $ 81 $ (144 ) $ 36,698

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jul. 31, 2023
Fair Value Measurements [Abstract]
Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis	The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of July 31, 2023 and 2022: July 31, 2023 Level 1 Level 2 Level 3 Total (in thousands) Assets: Available-for-sale securities - Corporate Bonds $ — $ 46,439 $ — $ 46,439 Available-for-sale securities - U.S. Treasury Bills 11,275 — — 11,275 Investment in equity securities 294 — — 294 Investment in Cyclo Therapeutics Inc. - Common stock 3,898 — — 3,898 Investment in Cyclo Therapeutics Inc. - Warrants 865 — — 865 Hedge funds — — 4,984 4,984 Convertible note receivable, related party — — 1,921 1,921 Total $ 16,332 $ 46,439 $ 6,905 $ 69,676 July 31, 2022 Level 1 Level 2 Level 3 Total (in thousands) Assets: Available-for-sale securities - Corporate Bonds $ — $ 36,698 $ — $ 36,698 Hedge funds — — 4,764 4,764 Total $ — $ 36,698 $ 4,764 $ 41,462
Schedule of Changes in the Fair Value of the Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs	The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3): Year Ended July 31, 2023 2022 (in thousands) Balance, beginning of period $ 4,764 $ 5,268 Total gain (loss) included in earnings 220 (504 ) Convertible note receivable, related party 2,000 — Total loss included in other comprehensive loss (79 ) — Balance, end of period $ 6,905 $ 4,764

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Jul. 31, 2023
Accounts Receivable [Abstract]
Schedule of Accounts Receivable	Accounts receivable consisted of the following: July 31, July 31, (in thousands) Accounts Receivable - Third Party $ 247 $ 196 Accounts Receivable - Related Party 211 158 Less Allowance for Doubtful Accounts (245 ) (197 ) Accounts Receivable, net $ 213 $ 157

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jul. 31, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: July 31, July 31, 2023 2022 (in thousands) Building and Improvements $ 2,505 $ 2,505 Other 68 68 2,573 2,573 Less Accumulated Depreciation (878 ) (803 ) Total $ 1,695 $ 1,770

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Jul. 31, 2023
Loss Per Share [Abstract]
Schedule of Dilutive Loss Per Share	The following table summarizes the Company’s potentially dilutive securities which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: Year Ended July 31, 2023 2022 Shares issuable upon exercise of stock options 388,409 1,021,277 Shares issuable upon vesting of restricted stock 684,766 1,507,373 1,073,175 2,528,650
Schedule of Basic and Diluted Loss Per Share	The following table summarizes the basic and diluted loss per share calculations (in thousands, except for share and per share amounts): Year Ended July 31, 2023 2022 Numerator: Net loss from continuing operations $ (8,693 ) $ (140,547 ) Net loss attributable to noncontrolling interests (339 ) (17,719 ) Numerator for net loss from continuing operations (8,354 ) (122,828 ) Numerator for discontinued operations 6,478 (1,830 ) Net loss attributable to Rafael Holdings, Inc. $ (1,876 ) $ (124,658 ) Denominator: Weighted average basic and diluted shares outstanding 23,263,211 19,767,342 Loss per share attributable to common stockholders Basic and diluted: Continuing operations $ (0.36 ) $ (6.22 ) Discontinued operations 0.28 (0.09 ) Total basic and diluted loss per share $ (0.08 ) $ (6.31 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Components of Loss before Income Taxes	The components of loss from continuing operations before income taxes are as follows: For the Years Ended 2023 2022 (in thousands) Domestic $ (6,056 ) $ (137,978 ) Foreign (2,689 ) (1,994 ) Loss before income taxes $ (8,745 ) $ (139,972 )
Schedule of Consolidated Statements of Operations and Comprehensive Loss	Benefit from income taxes as presented in the consolidated statements of operations and comprehensive loss consisted of the following: For the Year Ended 2023 2022 (in thousands) Current: Foreign $ 19 $ — Federal — — State (274 ) — Total current expense (benefit) (255 ) — Deferred: Foreign — — Federal — — State — — Total deferred expense — — Benefit from income taxes $ (255 ) $ —
Schedule of U.S. Federal Statutory Income Tax Rate	The differences between income taxes expected at the U.S. federal statutory income tax rate attributable to pretax loss from continuing operations and income taxes attributable to pretax loss from continuing operations are reported as follows: At July 31, 2023 2022 (in thousands) U.S. federal income tax at statutory rate $ (1,877 ) $ (29,514 ) State income tax (479 ) (8,752 ) Valuation allowance 2,958 35,001 Foreign tax rate differential (583 ) (459 ) Tax law change — — Permanent differences — 3,632 Rate change — — Sale of state NOLs (274 ) - Other - 92 Benefit from income taxes $ (255 ) $ —
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and deferred tax liabilities are as follows: At July 31, 2023 2022 (in thousands) Deferred tax assets: Net operating loss carryforwards $ 17,852 $ 15,170 Unrealized gain/loss 30,236 31,850 Depreciation (1 ) 1 R&D amortization 689 - Reserves and accruals 237 236 Stock-based compensation 1,858 1,839 Gross deferred tax assets 50,871 49,096 Less valuation allowance (50,871 ) (49,096 ) Total deferred tax assets — — Total deferred tax liabilities — — Deferred tax assets, net $ — $ —

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Jul. 31, 2023
Business Segment Information [Abstract]
Schedule of Operating Results for the Business Segments	Operating results for the business segments of the Company are as follows: (in thousands) Healthcare Real Estate Total Year Ended July 31, 2023 Revenues $ — $ 279 $ 279 (Loss) income from operations (15,121 ) 78 (15,043 ) Year Ended July 31, 2022 Revenues $ — $ 410 $ 410 (Loss) income from operations (60,658 ) 181 (60,477 )
Schedule of Revenues from these Non-United States Customers as a Percentage of Total Revenues	Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-U.S. customers as a percentage of total revenues, which are inclusive of revenue from discontinued operations, were as follows (revenues by country are determined based on the location of the related facility): Year Ended July 31, 2023 2022 Revenue from tenants located in Israel 53 % 7 %
Schedule of Net Long-Lived Assets	Net property, plant, and equipment and total assets held outside of the United States, which are located in Israel, were as follows: (in thousands) United States Israel Total July 31, 2023 Property, plant, and equipment, net $ 293 $ 1,402 $ 1,695 Total assets 95,244 3,585 98,829 July 31, 2022 Property, plant, and equipment, net $ 305 $ 1,465 $ 1,770 Total assets 114,053 4,267 118,320

Equity (Tables)

Equity (Tables)	12 Months Ended
	Jul. 31, 2023
Equity [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity for the Company is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding at July 31, 2021 683,414 $ 11.13 3.05 $ 26,982 Granted 518,304 20.54 9.25 — Cancelled / Forfeited (180,441 ) — — — Outstanding at July 31, 2022 1,021,277 12.11 4.47 — Granted 175,000 2.08 9.51 — Expired (589,205 ) — — — Cancelled / Forfeited (218,663 ) — — — Outstanding at July 31, 2023 388,409 $ 14.51 8.71 $ — Exercisable at July 31, 2023 65,456 $ 20.98 8.13 $ — Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding at July 31, 2021 — $ — — $ — Granted 5,266 3.82 9.76 — Outstanding at July 31, 2022 5,266 $ 3.82 9.76 $ — Granted — — — — Outstanding at July 31, 2023 5,266 $ 3.82 8.76 — Exercisable at July 31, 2023 2,633 $ 3.82 8.76 $ —
Schedule of Black-Scholes Option Pricing Model	The value of option grants is calculated using the Black-Scholes option pricing model with the following assumptions for options granted during the years ended July 31, 2023 and 2022: For the Year Ended July 31, 2023 2022 Risk-free interest rate 3.60% - 3.66% 0.67% - 1.7% Expected term (in years) 6.11 6.04 - 6.11 Expected volatility 95.00% 75% - 93% Expected dividend yield —% —%
Schedule of Grants of Restricted Shares of Class B Common Stock	A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below: Number of Non-vested Shares Weighted Average Grant Date Fair Value Outstanding at July 31, 2021 1,007,975 $ 46.77 Granted 1,533,311 4.24 Vested (90,608 ) 16.86 Cancelled / Forfeited (943,305 ) (48.50 ) Outstanding at July 31, 2022 1,507,373 $ 4.22 Granted 220,019 1.99 Vested (745,867 ) 3.37 Cancelled / Forfeited (296,759 ) (5.10 ) Non-vested shares at July 31, 2023 684,766 $ 4.04
Schedule of Stock-Based Compensation Expense	A summary of the stock-based compensation expense for the Company’s equity incentive plans is presented below (in thousands): For the Year Ended 2023 2022 General and administrative $ 3,044 $ 17,270 Research and development 194 791 Forfeiture of RSUs within general and administrative (931 ) (18,978 ) Forfeiture of RSUs within research and development (119 ) — Net stock-based compensation expense $ 2,188 $ (917 )

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jul. 31, 2023
Leases [Abstract]
Schedule of Future Contractual Minimum Lease Payments	The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of July 31, 2023, under non-cancellable operating leases which expire on various dates through 2025 are as follows: Year ending July 31, Related Parties Other Total (in thousands) 2024 $ 77 $ — $ 77 2025 78 — 78 Total Minimum Future Rental Income $ 155 $ — $ 155

Description of Business (Detail

Description of Business (Details) - USD ($) $ in Thousands			12 Months Ended
	Aug. 31, 2023	Feb. 09, 2023	Jul. 31, 2023	Mar. 21, 2023
Description of Business [Line Items]
Conversion debt (in Dollars)				$ 2,000
Company raised from third parties (in Dollars)	$ 925,000
Percentage of investment			95%
Ccapital stock percentage			42%
Rafael Medical Devices [Member]
Description of Business [Line Items]
Percentage of exchange	31.62%
CS Pharma Holdings, LLC [Member]
Description of Business [Line Items]
Percentage owned			50%
Interest percentage			45%
Pharma Holdings, LLC [Member]
Description of Business [Line Items]
Percentage owned			90%
Cornerstone Pharmaceuticals [Member]
Description of Business [Line Items]
Ccapital stock percentage			51%
Lipomedix Pharmaceuticals Ltd. [Member]
Description of Business [Line Items]
Ownership interest		11%
Lipomedix Pharmaceuticals Ltd. [Member] | Minimum [Member]
Description of Business [Line Items]
Ownership interest		84%
Lipomedix Pharmaceuticals Ltd. [Member] | Maximum [Member]
Description of Business [Line Items]
Ownership interest		95%

Description of Business (Deta_2

Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated	12 Months Ended
	Jul. 31, 2023
Broad Atlantic Associates, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100%
IDT R.E. Holdings Ltd. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	Israel
Percentage Owned	100%
Rafael Holdings Realty, Inc. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100%
Barer Institute, Inc. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100%	[1]
The Barer Institute, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100%	[1]
Hillview Avenue Realty, JV [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100%
Hillview Avenue Realty, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100%
Rafael Medical Devices, Inc. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100%
Levco Pharmaceuticals Ltd. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	Israel
Percentage Owned	95%	[2]
Farber Partners, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	93%
Pharma Holdings, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	90%
LipoMedix Pharmaceuticals Ltd. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	Israel
Percentage Owned	95%	[3]
Altira Capital & Consulting, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	67%
CS Pharma Holdings, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	45%	[4]
[1]In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities.[2]During Fiscal 2022, the Company discontinued further material investment in Levco.[3]On February 9, 2023, the Company increased its ownership interest in LipoMedix Pharmaceuticals Ltd. an additional 11% from 84% to 95%.[4]50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma and Pharma Holdings, collectively own securities representing 51% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). Refer to Note 4 for further details.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 22, 2022	Jul. 31, 2023	Jul. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Cash and cash equivalents (in Dollars)		$ 21,498	$ 26,537
Available-for-sale securities (in Dollars)		57,700
Received net proceeds (in Dollars)	$ 33,000
Bad debt expense (in Dollars)			4
Property purchase (in Dollars)	$ 49,400
Amortized debt issuance costs (in Dollars)		$ 0	$ 472
Tax benefit, percentage		50%
Revenue [Member] | Customer Concentration Risk [Member] | Customer [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage		42%	58%
Accounts Receivable [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Bad debt expense (in Dollars)		$ 110
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customers [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage		27%	24%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage		47%	47%
Related Party [Member] | Revenue [Member] | Credit Concentration Risk [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage		42%
Related Party [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Concentration risk percentage			58%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Long-Lived Assets	Jul. 31, 2023
Building and improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Long-Lived Assets [Line Items]
Estimated useful lives	40 years
Tenant improvements [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Long-Lived Assets [Line Items]
Estimated useful lives	7 years
Tenant improvements [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Long-Lived Assets [Line Items]
Estimated useful lives	15 years
Other (primarily equipment and furniture and fixtures) [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Long-Lived Assets [Line Items]
Estimated useful lives	5 years

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands		12 Months Ended
	Aug. 22, 2022	Jul. 31, 2023	Jul. 31, 2022
Discontinued Operations [Abstract]
Gross proceeds from property held for sale	$ 49,400	$ 49,400
Note payable		15,000
Repaying the note payable		33,000
Current portion of prepaid expenses and other current assets		0	$ 150
Non current portion of other assets			$ 1,300
Disposal gain on discontinued operations		6,800
Property carrying value		40,200
Transaction cost		1,200
Deferred rental income		$ 1,200

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of Classes of Assets and Liabilities - Discontinued Operations [Member] $ in Thousands	Jul. 31, 2022 USD ($)
Current assets held-for-sale
Building and Improvements	$ 45,437
Land	10,412
Furniture and Fixtures	1,145
Other	205
Property and equipment	57,199
Less Accumulated Depreciation	(17,005)
Property and equipment, net	40,194
Total current assets held-for-sale	40,194
Total assets held-for-sale	40,194
Current liabilities held-for-sale
Total current liabilities	$ 15,000

Discontinued Operations (Deta_3

Discontinued Operations (Details) - Schedule of Components Comprising Net Loss - Discontinued Operations [Member] - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Revenue from discontinued operations:
Total revenue from discontinued operations	$ 249	$ 3,499
Costs and expenses from discontinued operations:
Selling, general and administrative	468	2,683
Depreciation and amortization		1,317
Costs and expenses from discontinued operations, Loss from discontinued operations	(219)	(501)
Other income		157
Interest expense	(87)	(1,486)
Other income, Loss from discontinued operations	(306)	(1,830)
Gain on disposal of discontinued operations	6,784
Gain (loss) from discontinued operations	6,478	(1,830)
Rental – Third Party [Member]
Revenue from discontinued operations:
Total revenue from discontinued operations	68	644
Rental – Related Party [Member]
Revenue from discontinued operations:
Total revenue from discontinued operations	115	2,161
Parking [Member]
Revenue from discontinued operations:
Total revenue from discontinued operations	$ 66	$ 694

Investment in Cornerstone Pha_2

Investment in Cornerstone Pharmaceuticals (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions					1 Months Ended		12 Months Ended
	Jul. 31, 2022	Jun. 17, 2022	Oct. 01, 2021	Jan. 31, 2019	Oct. 28, 2021	Sep. 24, 2021	Jul. 31, 2023
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Principal amount (in Dollars)				$ 10
Ownership percentage in non-operating subsidiary							50%
Ownership interest percentage							8%
Total impairment loss (in Dollars)							$ 17.3
Noncontrolling interests (in Dollars)							79.1
Interest amount (in Dollars)							$ 10.4
CS Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Indirect interest in assets held, percentage							45%
Fully diluted equity interests							56%
Convertible promissory note, rate of interest				3.50%
Rafael Pharmaceuticals [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Percentage of outstanding capital stock							51%
Percentage of outstanding capital stock on fully diluted basis							42%
Fully diluted							10%
Impairment charge (in Dollars)					$ 79.1
Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Ownership percentage in non-operating subsidiary							90%
Ownership interest percentage							51%
Aggregate amount (in Dollars)						$ 25
Agreement accrues interest per annum		9%
Reserve amount (in Dollars)	$ 25
Other amounts (in Dollars)	2.6
Interest income (in Dollars)	$ 1.9
CS Pharma and Pharma Holdings [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Interest amount (in Dollars)							$ 6.9
Pharma Holdings [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Interest percentage							10%
Pharma Holdings [Member] | CS Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Interest percentage							10%
Warrant [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Warrant per share (in Dollars per share)							$ 1.25
Warrant [Member] | CS Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Fully diluted equity interests							70%
Series D Convertible Preferred Stock [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Pharma holdings holds shares (in Dollars)							$ 44
Series D Convertible Preferred Stock [Member] | CS Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Purchase of exercise the warrant, shares (in Shares)							16.7
Series D Preferred Stock [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Convertible preferred stock per share (in Dollars per share)							$ 1.25
Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Owned non-operating subsidiary							90%
CS Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Owned non-operating subsidiary							50%
Howard Jonas [Member] | Rafael Pharmaceuticals [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Fully diluted							10%
Howard Jonas [Member] | Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Owned non-operating subsidiary							10%
First Advance [Member] | Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Advance amount of debtor (in Dollars)						$ 1.9
Second Advance [Member] | Pharma Holdings, LLC [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Advance amount of debtor (in Dollars)			$ 23.1
Subsidiary Pharma Holdings [Member]
Investment in Cornerstone Pharmaceuticals (Details) [Line Items]
Held percentage							43%

Convertible Note Receivable, _2

Convertible Note Receivable, Related Party (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	May 22, 2023	Jul. 31, 2023	Mar. 21, 2023
Convertible Note Receivable, Related Party [Abstract]
Loaned amount (in Dollars)			$ 2,000
Bears interest rate			7.50%
Maturity date	Nov. 30, 2023
Retroactive interest rate		11%
Bear interest rate		14%
Promissory note interest rate		18%
Change in fair value (in Dollars)		$ 79
Interest income, promissory note (in Dollars)		$ 54

Investment in RP Finance, LLC (

Investment in RP Finance, LLC (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Oct. 31, 2021	Jul. 31, 2023	Jul. 31, 2022	Sep. 30, 2021	Jul. 31, 2021	Jun. 30, 2021	Nov. 30, 2020	Aug. 31, 2020	Feb. 03, 2020
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds				$ 5,000	$ 10,000	$ 10,000	$ 5,000	$ 5,000
Income from interest		$ 0	$ 1,900
Percentage of ownership interest			37.50%
Cumulative funds description		the Company has funded a cumulative total of $9.375 million in accordance with its 37.5% ownership interests in RP Finance.
Rafael Pharmaceuticals [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds				$ 5,000			$ 5,000	$ 5,000
Percentage of issued and outstanding shares		12%
Related party receivable			$ 9,375
Line of Credit Agreement [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds									$ 50,000,000
Description line of credit facility		The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. The Instrument owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. The remaining 25% equity interests in RP Finance are owned by other stockholders of Cornerstone Pharmaceuticals.
RP finance [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Income from interest		$ 0	$ 575
Percentage of ownership interest		37.50%	37.50%
Equity loss	$ 575
Equity method investment		$ 0	$ 0

Investment in LipoMedix Pharm_2

Investment in LipoMedix Pharmaceuticals Ltd (Details) - USD ($)			12 Months Ended
	Feb. 09, 2023	Nov. 15, 2021	Jul. 31, 2023	Jul. 31, 2022	Nov. 11, 2022	Sep. 01, 2021	Mar. 31, 2021
Investment in LipoMedix Pharmaceuticals Ltd (Details) [Line Items]
Issued and outstanding ordinary shares, percentage			95%
Maturity date			Sep. 01, 2021		Nov. 11, 2022
Investment or financing interest rate						15%
Share price (in Dollars per share)	$ 0.03	$ 0.1878
Payments to acquire or invest in ordinary shares			$ 1,586,000
Aggregate purchase price	$ 2,100,000
Investment owned percentage	95%
Noncontrolling interest	$ 16,000		$ 8,000
LipoMedix Pharmaceuticals, Ltd. [Member]
Investment in LipoMedix Pharmaceuticals Ltd (Details) [Line Items]
Investment or financing principal amount							$ 400,000,000
Investment or financing interest rate							8%
Purchase of ordinary shares (in Shares)	70,000,000	15,975,000	15,975,000
Principal amount outstanding					$ 400,000
Accrued interest					$ 21,800
Cash payment			$ 2,600,000
LipoMedix SPA [Member]
Investment in LipoMedix Pharmaceuticals Ltd (Details) [Line Items]
Payments to acquire or invest in ordinary shares	$ 2,100,000	$ 3,000,000
Aggregate purchase price			$ 3,000,000
Maximum [Member]
Investment in LipoMedix Pharmaceuticals Ltd (Details) [Line Items]
Investment owned percentage			84%
Minimum [Member]
Investment in LipoMedix Pharmaceuticals Ltd (Details) [Line Items]
Investment owned percentage	5%		16%
Warrant [Member]
Investment in LipoMedix Pharmaceuticals Ltd (Details) [Line Items]
Purchase of ordinary shares (in Shares)					15,975,000
Share price (in Dollars per share)					$ 0.1878

Investment in Day Three Labs _2

Investment in Day Three Labs Inc. (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Apr. 07, 2023
INVESTMENT IN DAY THREE LABS INC. [Member]
Investment in Day Three Labs Inc. (Details) [Line Items]
Purchase of common stock		4,302,224
Outstanding shares, percentage		38%
Diluted basis, percentage		33.333%
Purchase price		$ 3,000
Warrant exercisable		7,528,893
Aggregate purchase price		$ 3,000
Expires term		5 years
Equity in loss of Day Three Labs Inc.	$ 203
INVESTMENT IN DAY THREE LABS INC. [Member]
Investment in Day Three Labs Inc. (Details) [Line Items]
Ownership interest	38%

Investment in Cyclo Therapeut_3

Investment in Cyclo Therapeutics, Inc. (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Oct. 20, 2023	Aug. 01, 2023	Jun. 01, 2023	Jul. 31, 2023	Apr. 30, 2023	Feb. 09, 2023	Nov. 11, 2022	Nov. 15, 2021
Investment in Cyclo Therapeutics, Inc. (Details) [Line Items]
Purchase agreement, description				The Company purchased from Cyclo (i) 2,514,970 common shares (the “Purchased Shares”) and (ii) a warrant to purchase 2,514,970 common shares with an exercise price of $0.71 per share (the “Cyclo Warrant”), at a combined purchase price equal to $0.835 per Purchased Share and Cyclo Warrant to purchase one share, for an aggregate purchase price of $2.1 million.
Additional common shares (in Shares)	2,766,467		4,000,000
Warrant purchase shares (in Shares)		4,000,000	4,000,000
Aggregate purchase amount	$ 1,785,629	$ 5,000,000	$ 5,000,000
Exercise price (in Dollars per share)						$ 0.03		$ 0.1878
Purchase shares (in Shares)		4,000,000
Common shares (in Shares)	2,514,970
Exercise price (in Dollars per share)				$ 1.75	$ 1.75
Exercise price (in Dollars per share)						$ 0.03
Total aggregate fair value				$ 4,763,102
Investment in Cyclo Therapeutics, Inc. [Member]
Investment in Cyclo Therapeutics, Inc. (Details) [Line Items]
Exercise price (in Dollars per share)			$ 1.25
Ownership percentage		34%		16%
Exercise price (in Dollars per share)	$ 0.71
Exercise price (in Dollars per share)	$ 0.95
Aggregate fair value				$ 3,898,204
Warrant [Member]
Investment in Cyclo Therapeutics, Inc. (Details) [Line Items]
Exercise price (in Dollars per share)							$ 0.1878
Warrant [Member] | Investment in Cyclo Therapeutics, Inc. [Member]
Investment in Cyclo Therapeutics, Inc. (Details) [Line Items]
Aggregate fair value				864,898
Investment in Cyclo Therapeutics, Inc. [Member]
Investment in Cyclo Therapeutics, Inc. (Details) [Line Items]
Unrealized gain investment				2,100
Cyclo SPA [Member]
Investment in Cyclo Therapeutics, Inc. (Details) [Line Items]
Unrealized gain investment				$ 2,700

Investment in Cyclo Therapeut_4

Investment in Cyclo Therapeutics, Inc. (Details) - Schedule of Fair Value Method Investment - Cyclo [Member] $ in Thousands	Jul. 31, 2023 USD ($)
Fair Value, Separate Account Investment [Line Items]
Ownership Percentage	16%
Aggregate Fair Value	$ 4,763,102

Investment in Cyclo Therapeut_5

Investment in Cyclo Therapeutics, Inc. (Details) - Schedule of Consolidated Financial Information - Investment in Cyclo Therapeutics, Inc. [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed Financial Statements, Captions [Line Items]
Revenue	$ 117,118	$ 541,886	$ 269,529	$ 736,790
Loss from operations	(4,632,942)	(3,456,024)	(9,640,074)	(6,390,481)
Net loss	$ (4,636,455)	$ (3,451,990)	$ (9,643,540)	$ (6,223,581)

Investment (Details)

Investment (Details) $ in Thousands	Jul. 31, 2023 USD ($)
Investment [Abstract]
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax	$ 154
Maturity year

Investment (Details) - Schedule

Investment (Details) - Schedule of Available-for-Sale Securities - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Investment (Details) - Schedule of Available-for-Sale Securities [Line Items]
Amortized cost	$ 59,988	$ 36,761
Gross unrealized gains	4,386	81
Gross unrealized (losses)	(4,739)	(144)
Fair value	59,635	36,698
U.S. Treasury Bills [Member]]
Investment (Details) - Schedule of Available-for-Sale Securities [Line Items]
Amortized cost	11,222
Gross unrealized gains	53
Gross unrealized (losses)
Fair value	11,275
Corporate bonds [Member]]
Investment (Details) - Schedule of Available-for-Sale Securities [Line Items]
Amortized cost	46,766	36,761
Gross unrealized gains	4,333	81
Gross unrealized (losses)	(4,660)	(144)
Fair value	46,439	$ 36,698
Convertible note receivable, related party [Member]]
Investment (Details) - Schedule of Available-for-Sale Securities [Line Items]
Amortized cost	2,000
Gross unrealized gains
Gross unrealized (losses)	(79)
Fair value	$ 1,921

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Fair Value Measurements [Abstract]
Investment owned at fair value	$ 100	$ 500
Investment in equity securities impairment loss	$ 334	$ 0

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Total	$ 69,676	$ 41,462
Corporate Bond Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities	46,439	36,698
US Treasury Bill Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities	11,275
Equity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	294
Common Stock [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	3,898
Warrant [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	865
Hedge Funds [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	4,984	4,764
Convertible Note Receivable [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities	1,921
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Total	16,332
Level 1 [Member] | Corporate Bond Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities
Level 1 [Member] | US Treasury Bill Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities	11,275
Level 1 [Member] | Equity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	294
Level 1 [Member] | Common Stock [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	3,898
Level 1 [Member] | Warrant [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	865
Level 1 [Member] | Hedge Funds [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 1 [Member] | Convertible Note Receivable [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Total	46,439	36,698
Level 2 [Member] | Corporate Bond Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities	46,439	36,698
Level 2 [Member] | US Treasury Bill Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities
Level 2 [Member] | Equity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 2 [Member] | Common Stock [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 2 [Member] | Warrant [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 2 [Member] | Hedge Funds [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 2 [Member] | Convertible Note Receivable [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Total	6,905	4,764
Level 3 [Member] | Corporate Bond Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities
Level 3 [Member] | US Treasury Bill Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities
Level 3 [Member] | Equity Securities [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 3 [Member] | Common Stock [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 3 [Member] | Warrant [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities
Level 3 [Member] | Hedge Funds [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Investment in securities	4,984	$ 4,764
Level 3 [Member] | Convertible Note Receivable [Member]
Fair Value Measurements (Details) - Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis [Line Items]
Available-for-sale securities	$ 1,921

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of the Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Balance, beginning of period	$ 4,764	$ 5,268
Total gain (loss) included in earnings	220	(504)
Convertible note receivable, related party	2,000
Total loss included in other comprehensive loss	(79)
Balance, end of period	$ 6,905	$ 4,764

Accounts Receivable (Details) -

Accounts Receivable (Details) - Schedule of Accounts Receivable - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Schedule of Accounts Receivable [Abstract]
Accounts Receivable - Third Party	$ 247	$ 196
Accounts Receivable - Related Party	211	158
Less Allowance for Doubtful Accounts	(245)	(197)
Accounts Receivable, net	$ 213	$ 157

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Property and Equipment [Member]
Property and Equipment (Details) [Line Items]
Depreciation expense	$ 78	$ 72

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - Property and Equipment [Member] - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Property, Plant and Equipment [Line Items]
Building and Improvements	$ 2,505	$ 2,505
Other	68	68
Property and equipment, gross	2,573	2,573
Less Accumulated Depreciation	(878)	(803)
Total	$ 1,695	$ 1,770

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of Dilutive Loss Per Share - shares	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule of Dilutive Loss Per Share [Abstract]
Shares issuable upon exercise of stock options	388,409	1,021,277
Shares issuable upon vesting of restricted stock	684,766	1,507,373
Dilutive loss per share, total	1,073,175	2,528,650

Loss Per Share (Details) - Sc_2

Loss Per Share (Details) - Schedule of Basic and Diluted Loss Per Share - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Numerator:
Net loss from continuing operations	$ (8,693)	$ (140,547)
Net loss attributable to noncontrolling interests	(339)	(17,719)
Numerator for net loss from continuing operations	(8,354)	(122,828)
Numerator for discontinued operations	6,478	(1,830)
Net loss attributable to Rafael Holdings, Inc.	$ (1,876)	$ (124,658)
Denominator:
Weighted average basic shares outstanding (in Shares)	23,263,211	19,767,342
Basic and diluted:
Continuing operations - basic (in Dollars per share)	$ (0.36)	$ (6.22)
Discontinued operations - basic (in Dollars per share)	0.28	(0.09)
Basic loss per share (in Dollars per share)	$ (0.08)	$ (6.31)

Loss Per Share (Details) - Sc_3

Loss Per Share (Details) - Schedule of Basic and Diluted Loss Per Share (Parentheticals) - $ / shares	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule of Basic and Diluted Loss Per Share [Abstract ]
Weighted average diluted shares outstanding (in Shares)	23,263,211	19,767,342
Continuing operations - diluted	$ (0.36)	$ (6.22)
Discontinued operations - diluted	0.28	(0.09)
Diluted loss per share	$ (0.08)	$ (6.31)

Note Payable, Held-For-Sale (De

Note Payable, Held-For-Sale (Details) - Notes Payable [Member] - USD ($) $ in Thousands		12 Months Ended
	Aug. 22, 2022	Jul. 31, 2023	Jul. 31, 2022	Jul. 29, 2022	Jul. 09, 2021
Note Payable, Held-For-Sale (Details) [Line Items]
Note payable					$ 15,000
Note payable bears interest rate, description		The Note Payable bore interest at a rate per annum equal to seven and one-quarter percent (7.25%) from July 9, 2021 through July 31, 2021 and thereafter at an interest rate per annum equal to the 30-day LIBOR Rate, as published in The Wall Street Journal, plus 6.90% per annum, but in no event less than seven and one-quarter percent (7.25%) per annum. The Note Payable was due on August 1, 2022, subject to the Company’s option to extend the maturity date until August 1, 2023 for a fee equal to three-quarters of one percent (0.75%) of the Note Payable.
Maturity date		Nov. 01, 2022
Paid extension fee				$ 37,500
Paid off the notes payable	$ 15,000
Repayment of interest	$ 87,000
Interest expense		$ 87	$ 1,200
Unamortized debt issuance costs		0	0
Amortization of debt discount		$ 0	$ 472

Related Party Transactions (Det

Related Party Transactions (Details)						12 Months Ended
	Jul. 31, 2023 USD ($) ft² shares	Feb. 09, 2023 USD ($) $ / shares shares	Jul. 06, 2022 USD ($) $ / shares shares	Nov. 15, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Jul. 31, 2023 USD ($) ft² shares	Jul. 31, 2022 USD ($) shares	May 22, 2023	Mar. 21, 2023 USD ($)	Jun. 06, 2022 $ / shares
Related Party Transactions (Details) [Line Items]
Related party expenses						$ 313,000	$ 343,000
Due to related parties						$ 70,000	69,000
Area of land (in Square Feet) | ft²	80,000					80,000
Discontinued operations						$ 102,000
Approximately discontinued operations	$ 19,000					19,000	2,000,000
Allowance for uncollectible	$ 720,000					720,000	720,000
Related party receivable							$ 720,000
Accrued interest									$ 2,000,000
Maturity date								Nov. 30, 2023
Payroll costs						$ 10,000
Revenue percentage						42%	58%
Recognized loss						$ 0	$ 575,000
Consideration amount					$ 5,000,000
Warrants percentage					20%
Exercise price (in Dollars per share) | $ / shares										$ 22.91
Shares issued (in Shares) | shares			3,225,806
Price per share (in Dollars per share) | $ / shares			$ 1.86
Aggregate sale price			$ 6,000,000
Aggregate voting percentage	51.30%
Ordinary shares, purchased (in Shares) | shares		70,000,000
Ordinary shares, price per share (in Dollars per share) | $ / shares		$ 0.03
Aggregate purchase price		$ 2,100,000
Ownership percentage		95%
Carrying amount of the noncontrolling interest		$ 16,000
Investment amount						1,600,000
Profit on investment in equity securities						$ 309,000
LipoMedix [Member]
Related Party Transactions (Details) [Line Items]
Ownership percentage				84%
Noncontrolling interest percentage		5%		16%
Israel [Member]
Related Party Transactions (Details) [Line Items]
Area of land (in Square Feet) | ft²	3,600					3,600
Class B Common Stock [Member]
Related Party Transactions (Details) [Line Items]
Purchase of shares (in Shares) | shares					218,245
Common stock, shares issued (in Shares) | shares	23,635,709					23,635,709	23,712,449
Class A Common Stock [Member]
Related Party Transactions (Details) [Line Items]
Common stock, shares issued (in Shares) | shares	787,163					787,163	787,163
RP Finance [Member]
Related Party Transactions (Details) [Line Items]
Income from its ownership percentage	37.50%					37.50%	37.50%
Chief Executive Officer [Member] | Class A Common Stock [Member]
Related Party Transactions (Details) [Line Items]
Common stock, shares issued (in Shares) | shares	787,163					787,163
IDT Corporation [Member]
Related Party Transactions (Details) [Line Items]
Discontinued operations						$ 211,000
Approximately discontinued operations							$ 2,100,000
IDT Owed [Member]
Related Party Transactions (Details) [Line Items]
Rent and parking expenses						$ 210,000	157,000
Cornerstone Pharmaceuticals [Member]
Related Party Transactions (Details) [Line Items]
Billed amount							$ 120,000
LipoMedix Pharmaceuticals, Ltd. [Member]
Related Party Transactions (Details) [Line Items]
Purchase of shares (in Shares) | shares				15,975,000
Outstanding loan balance				$ 400,000
Accrued interest				21,800
Due from owed amount				3,000,000
Cash payment				$ 2,600,000

Income Taxes (Details)

Income Taxes (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Carryforwards of domestic operations	$ 63,200
State of operations	40,400
Foreign of operations	$ 7,600
Taxable income	80%
Approximately	$ 274

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Components of Loss before Income Taxes - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule Of Components Of Loss Before Income Taxes Abstract
Domestic	$ (6,056)	$ (137,978)
Foreign	(2,689)	(1,994)
Loss before income taxes	$ (8,745)	$ (139,972)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Current:
Foreign	$ 19
Federal
State	(274)
Total current expense (benefit)	(255)
Deferred:
Foreign
Federal
State
Total deferred expense
Benefit from income taxes	$ (255)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of U.S. Federal Statutory Income Tax Rate - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule Of USFederal Statutory Income Tax Rate Abstract
U.S. federal income tax at statutory rate	$ (1,877)	$ (29,514)
State income tax	(479)	(8,752)
Valuation allowance	2,958	35,001
Foreign tax rate differential	(583)	(459)
Tax law change
Permanent differences		3,632
Rate change
Sale of state NOLs	(274)
Other		92
Benefit from income taxes	$ (255)

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Schedule Of Deferred Tax Assets And Liabilities Abstract
Net operating loss carryforwards	$ 17,852	$ 15,170
Unrealized gain/loss	30,236	31,850
Depreciation	(1)	1
R&D amortization	689
Reserves and accruals	237	236
Stock-based compensation	1,858	1,839
Gross deferred tax assets	50,871	49,096
Less valuation allowance	(50,871)	(49,096)
Total deferred tax assets
Total deferred tax liabilities
Deferred tax assets, net

Business Segment Information (D

Business Segment Information (Details)	12 Months Ended
	Jul. 31, 2023
Business Segment Information [Abstract]
Number of operating segments	2

Business Segment Information _2

Business Segment Information (Details) - Schedule of Operating Results for the Business Segments - Business Segment [Member] - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Segment Reporting Information [Line Items]
Revenues	$ 279	$ 410
(Loss) income from operations	(15,043)	(60,477)
Real Estate [Member]
Segment Reporting Information [Line Items]
Revenues	279	410
(Loss) income from operations	78	181
Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues
(Loss) income from operations	$ (15,121)	$ (60,658)

Business Segment Information _3

Business Segment Information (Details) - Schedule of Revenues from these Non-United States Customers as a Percentage of Total Revenues	Jul. 31, 2023	Jul. 31, 2022
Segment Reporting Information [Line Items]
Revenue from tenants located in Israel	53%	7%

Business Segment Information _4

Business Segment Information (Details) - Schedule of Net Long-Lived Assets - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Segment Reporting Information [Line Items]
Property, plant, and equipment, net	$ 1,695	$ 1,770
Total assets	98,829	118,320
United States [Member]
Segment Reporting Information [Line Items]
Property, plant, and equipment, net	293	305
Total assets	95,244	114,053
Israel [Member]
Segment Reporting Information [Line Items]
Property, plant, and equipment, net	1,402	1,465
Total assets	$ 3,585	$ 4,267

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Vendor payment	$ 113

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Thousands

12 Months Ended

Jan. 31, 2023

Jul. 31, 2022

Jul. 06, 2022

Jun. 14, 2022

Jun. 13, 2022

Feb. 01, 2022

Jan. 31, 2022

Nov. 21, 2021

Jun. 01, 2021

Dec. 07, 2020

Dec. 04, 2020

Jul. 31, 2023

Jul. 31, 2022

Jul. 31, 2021

Apr. 30, 2023

Feb. 09, 2023

Nov. 28, 2022

Jun. 06, 2022

Jan. 19, 2022

Aug. 19, 2021

May 27, 2021

Equity (Details) [Line Items]

Repurchase the authorizing shares (in Dollars)

$ 5,000

$ 5,000

Price per share (in Dollars per share)

$ 1.75

$ 1.75

Restricted stock units, description

On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the “Institutional Shares”), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregate gross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses.

Proceeds from the issuance of shares (in Dollars)

$ 98,000

Deducting transaction costs (in Dollars)

6,200

Aggregate sale price (in Dollars)

$ 6,000

Term period

5 years

Common stock value (in Dollars)

$ 600,000

Total unrecognized compensation cost (in Dollars)

$ 5

Recognized compensation cost over next period

1 year 5 months 8 days

Stock options granted (in Dollars per share)

$ 2.08

$ 20.54

Per share value (in Dollars per share)

$ 0.03

Restricted shares

33,360

Share based compensation cost (in Dollars)

$ 2,188

$ (917)

Restricted stock shares issued

452,130

986,835

Restricted shares percentage

24%

Expense amount (in Dollars)

307,913

Share based compensation cost (in Dollars)

$ 915

Exercise price (in Dollars per share)

$ 22.91

Proceeds from the issuance of shares (in Dollars)

99,170

Exercise price (in Dollars per share)

$ 22.91

Securities Purchase Agreement [Member]

Equity (Details) [Line Items]

Proceeds from issuance of warrants (in Dollars)

8,200

2018 Equity Incentive Plan [Member]

Equity (Details) [Line Items]

Aggregate gross proceeds (in Dollars)

$ 5,000

2021 Plan [Member]

Equity (Details) [Line Items]

Issuance of shares

953,516

2022 Plan [Member]

Equity (Details) [Line Items]

Issuance of shares

4,734

Common stock shares issued

10,000

Per share value (in Dollars per share)

$ 4.02

Equity Incentive Plan [Member]

Equity (Details) [Line Items]

Share based compensation cost (in Dollars)

$ 151

Warrant [Member]

Equity (Details) [Line Items]

Purchase of warrants granted, percentage

20%

Warrants outstanding

26,189

Exercise price (in Dollars per share)

$ 22.91

Stock Options [Member]

Equity (Details) [Line Items]

Total unrecognized compensation cost (in Dollars)

$ 1,300

$ 1,300

Recognized compensation cost over next period

3 years 2 months 12 days

Stock options granted (in Dollars per share)

$ 1.58

$ 3.29

Restricted Stock [Member]

Equity (Details) [Line Items]

Total unrecognized compensation cost (in Dollars)

$ 1,800

Recognized compensation cost over next period

4 years

Class B Common Stock [Member]

Equity (Details) [Line Items]

Repurchase the authorizing shares (in Dollars)

$ 5,000

Price per share (in Dollars per share)

$ 1.86

Sale of common stock (in Dollars)

$ 250,000

Sale of stock issued

3,225,806

48,859

Share issued

112,501

Share per price (in Dollars per share)

$ 44.42

Annual base salary (in Dollars)

260,000

Restricted shares (in Dollars)

$ 250,000

Common stock value (in Dollars)

$ 237

$ 236

$ 237

Proceeds from the issuance of shares (in Dollars)

$ 2,000

Class B Common Stock [Member] | Securities Purchase Agreement [Member]

Equity (Details) [Line Items]

Sale of stock issued

567,437

Sale of stock price per share (in Dollars per share)

$ 22.91

Aggregate purchase price (in Dollars)

$ 13,000

Aggregate shares of common stock

218,245

Cash consideration (in Dollars)

$ 5,000

Class B Common Stock [Member] | 2021 Plan [Member]

Equity (Details) [Line Items]

Issuance of shares

1,919,025

Grant of awards

696,770

Common stock shares issued

2,615,795

Class B Common Stock [Member] | Warrant [Member]

Equity (Details) [Line Items]

Warrants to purchase

113,487

Warrants exercised

87,298

Board of Directors [Member]

Equity (Details) [Line Items]

Restricted shares

18,336

Restricted stock shares issued

120,019

Board of Directors [Member] | Equity Incentive Plan [Member]

Equity (Details) [Line Items]

Restricted shares

15,024

Chief Financial Officer [Member]

Equity (Details) [Line Items]

Restricted stock shares issued

100,000

Cancelled or forfeited shares

285,036

Chief Financial Officer [Member] | Equity Incentive Plan [Member]

Equity (Details) [Line Items]

Cancelled or forfeited shares

296,759

Chief Executive Officer [Member]

Equity (Details) [Line Items]

Share based compensation cost (in Dollars)

$ 19,000

Severance expense (in Dollars)

$ 5,000

IDT [Member] | Warrant [Member]

Equity (Details) [Line Items]

Warrants exercised

43,649

Equity (Details) - Schedule of

Equity (Details) - Schedule of Stock Option Activity - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule of Stock Option Activity [Abstract]
Number of Options, Outstanding, Beginning balance	1,021,277	683,414
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 12.11	$ 11.13
Weighted Average Remaining Contractual Term (in years), Beginning balance		3 years 18 days
Aggregate Intrinsic Value, Outstanding, Beginning balance		$ 26,982
Number of Options, Granted	175,000	518,304
Weighted Average Exercise Price, Granted	$ 2.08	$ 20.54
Weighted Average Remaining Contractual Term (in years), Granted	9 years 6 months 3 days	9 years 3 months
Aggregate Intrinsic Value, Outstanding, Granted
Number of Options, Outstanding, Expired	(589,205)
Weighted Average Exercise Price, Outstanding, Expired
Weighted Average Remaining Contractual Term (in years), Outstanding, Expired
Aggregate Intrinsic Value, Outstanding, Expired
Number of Options, Cancelled / Forfeited	(218,663)	(180,441)
Weighted Average Exercise Price, Cancelled / Forfeited
Weighted Average Remaining Contractual Term (in years), Cancelled / Forfeited
Aggregate Intrinsic Value, Cancelled / Forfeited
Number of Options, Outstanding, Ending balance	388,409	1,021,277
Weighted Average Exercise Price, Outstanding, Ending balance	$ 14.51	$ 12.11
Weighted Average Remaining Contractual Term (in years), Ending balance	8 years 8 months 15 days	4 years 5 months 19 days
Aggregate Intrinsic Value, Outstanding, Ending balance
Number of Options, Exercisable	65,456
Weighted Average Exercise Price, Exercisable	$ 20.98
Weighted Average Remaining Contractual Term (in years), Outstanding, Exercisable	8 years 1 month 17 days
Aggregate Intrinsic Value, Outstanding, Exercisable
Rafael Medical Devices, Inc [Member]
Schedule of Stock Option Activity [Abstract]
Number of Options, Outstanding, Beginning balance	5,266
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 3.82
Weighted Average Remaining Contractual Term (in years), Beginning balance
Aggregate Intrinsic Value, Outstanding, Beginning balance
Number of Options, Granted		5,266
Weighted Average Exercise Price, Granted		$ 3.82
Weighted Average Remaining Contractual Term (in years), Granted		9 years 9 months 3 days
Aggregate Intrinsic Value, Outstanding, Granted
Number of Options, Outstanding, Ending balance	5,266	5,266
Weighted Average Exercise Price, Outstanding, Ending balance	$ 3.82	$ 3.82
Weighted Average Remaining Contractual Term (in years), Ending balance	8 years 9 months 3 days	9 years 9 months 3 days
Aggregate Intrinsic Value, Outstanding, Ending balance
Number of Options, Exercisable	2,633
Weighted Average Exercise Price, Exercisable	$ 3.82
Weighted Average Remaining Contractual Term (in years), Outstanding, Exercisable	8 years 9 months 3 days
Aggregate Intrinsic Value, Outstanding, Exercisable

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Black-Scholes Option Pricing Model	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule of Black-Scholes Option Pricing Model [Abstract]
Expected term (in years)	6 years 1 month 9 days
Expected volatility	95%
Expected dividend yield
Minimum [Member]
Schedule of Black-Scholes Option Pricing Model [Abstract]
Risk-free interest rate	3.60%	0.67%
Expected term (in years)		6 years 14 days
Expected volatility		75%
Maximum [Member]
Schedule of Black-Scholes Option Pricing Model [Abstract]
Risk-free interest rate	3.66%	1.70%
Expected term (in years)		6 years 1 month 9 days
Expected volatility		93%

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of Grants of Restricted Shares of Class B Common Stock - $ / shares	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule of Grants of Restricted Shares of Class B Common Stock [Abstract]
Number of Non-vested Shares, Beginning balance	1,507,373	1,007,975
Weighted Average Grant Date Fair Value, Beginning balance	$ 4.22	$ 46.77
Number of Non-vested Shares, Granted	220,019	1,533,311
Weighted Average Grant Date Fair Value, Granted	$ 1.99	$ 4.24
Number of Non-vested Shares, Vested	(745,867)	(90,608)
Weighted Average Grant Date Fair Value, Vested	$ 3.37	$ 16.86
Number of Non-vested Shares, Cancelled / Forfeited	(296,759)	(943,305)
Weighted Average Grant Date Fair Value, Cancelled / Forfeited	$ (5.1)	$ (48.5)
Number of Non-vested Shares, Ending balance	684,766	1,507,373
Weighted Average Grant Date Fair Value, Ending balance	$ 4.04	$ 4.22

Equity (Details) - Schedule o_4

Equity (Details) - Schedule of Stock-Based Compensation Expense - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Schedule of Stock-Based Compensation Expense [Abstract]
General and administrative	$ 3,044	$ 17,270
Research and development	194	791
Forfeiture of RSUs within general and administrative	(931)	(18,978)
Forfeiture of RSUs within research and development	(119)
Net stock-based compensation expense	$ 2,188	$ (917)

Leases (Details)

Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Leases [Abstract]
Net operating leases with initial term expiration dates ,description	The Company is the lessor of the Israeli property which is leased to tenants under net operating leases with a term expiration date within 2025.
Comprehensive loss	$ 0.3	$ 0.3
Related parties terminate leases, description	A related party has the right to terminate the Israeli lease upon four months’ notice.

Leases (Details) - Schedule of

Leases (Details) - Schedule of Future Contractual Minimum Lease Payments $ in Thousands	Jul. 31, 2023 USD ($)
Leases (Details) - Schedule of Future Contractual Minimum Lease Payments [Line Items]
2024	$ 77
2025	78
Total Minimum Future Rental Income	155
Related Parties [Member]
Leases (Details) - Schedule of Future Contractual Minimum Lease Payments [Line Items]
2024	77
2025	78
Total Minimum Future Rental Income	155
Other [Member]
Leases (Details) - Schedule of Future Contractual Minimum Lease Payments [Line Items]
2024
2025
Total Minimum Future Rental Income

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Aug. 01, 2023	Aug. 28, 2023	Jul. 31, 2023
Subsequent Events (Details) [Line Items]
Deposit from outside third party			$ 825
Additional amount	$ 100
Sale of units	$ 925
Class B Common Stock
Subsequent Events (Details) [Line Items]
Restricted shares (in Shares)		111,408
Subsequent Event [Member] | Rafael Medical Devices, LLC [Member]
Subsequent Events (Details) [Line Items]
Ownership interests, percentage	53.40%